医薬品開発業務受託機関（CRO）サービス市場規模、セグメント分析、2030年までの世界予測

本調査レポートは、医薬品開発業務受託機関（CRO）サービス市場をサービスタイプ（臨床研究サービス、早期開発サービス、ラボサービス、コンサルティングサービス、データマネジメントサービス）、モダリティ（低分子、生物製剤、バイオシミラー、医療機器）、エンドユーザー（製薬・バイオ医薬品企業、医療機器企業、学術機関）、地域範囲（北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。レポートでは、CROサービス市場の成長に影響を与える推進要因、制約要因、課題、機会など、主要な要因に関する詳細な情報を網羅しています。主要業界プレーヤーの徹底的な分析により、各社の事業概要、サービス、主要戦略、協業、パートナーシップ、契約に関する洞察が得られています。新製品の発売、協業、パートナーシップ、買収は、医薬品開発業務受託機関（CRO）サービス市場に関連する最近の動向です。

本レポートは、医薬品開発業務受託機関（CRO）サービス市場全体とそのサブセグメントの収益数値に最も近い近似値を提供することで、市場リーダー企業や新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、自社のポジショニングを改善し、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、機会、課題に関する情報を提供することを可能にします。

医薬品開発業務受託機関（CRO）サービス市場は、2025年の846億1,000万米ドルから2030年には1,259億5,000万米ドルに達し、予測期間中は年平均成長率（CAGR）8.3%で成長すると見込まれています。

市場成長の主要因としては、細胞・遺伝子治療のパイプラインの拡大と、プレシジョン・メディシンへの注目度の高まりが挙げられます。これらの要因により、スポンサーは、複雑な設計、ゲノムスクリーニング、カスタマイズ可能な物流、社内では対応が難しい必須の長期フォローアップ機能に対応できるCROパートナーを求めるようになると予想されます。プレシジョン・プログラムは患者コホートを細分化し、登録期間を短縮するため、統合されたCROラボネットワークと世界的な治験実施施設のカバレッジが、タイムラインとデータ品質の決定的な要因となります。規制当局と保険支払者が堅牢でリアルタイムのエビデンスを求める中、スポンサーは開発リスクを軽減するために、高度なラボ、データサイエンス、リアルワールドエビデンス機能を備えた臨床業務を提供するCROへの依存度を高めています。

The Contract Research Organization (CRO) services market is expected to reach USD 125.95 billion in 2030 from USD 84.61 billion in 2025, at a CAGR of 8.3% during the forecast period. The key factors contributing to market growth include the expanding pipeline of cell & gene therapies and the growing focus on precision medicine. These factors are expected to fuel sponsors towards CRO partners that can handle complex designs, genomic screening, customizable logistics, and mandatory long-term follow-up capabilities that are challenging to utilize in-house. Precision programs fragment patient cohorts and shorten enrollment windows, making integrated CRO-lab networks and global site coverage decisive for timelines and data quality. As regulators and payers demand robust, real-time evidence, sponsors increasingly depend on CROs that offer clinical operations with advanced lab, data science, and RWE capabilities to de-risk development.

By service type, the early phase development services segment accounted for the largest share of the CRO services market in 2024.

Based on service type, the CRO services market is segmented into clinical research services, early phase development services, laboratory services, consulting services, and data management services. In 2024, the early phase development services segment accounted for the largest share of the market. The current pipeline is focused on developing novel biologics, CGT, and targeted modalities that require specialized toxicology, DMPK, bioanalysis, and safety pharmacology, which several sponsors prefer to outsource to reach the IND (investigational new drug) stage faster.

By end user, the pharmaceutical & biopharmaceutical companies accounted for the largest share in the CRO services market in 2024.

Based on end user, the CRO services market is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. In 2024, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the CRO services market. The large share of this end-user segment can be attributed to the large number of drug pipeline products of pharma and biotech companies. Moreover, CROs deliver speed, scale, and flexible cost bases, attracting end users.

By region, North America accounted for the largest share of the market in 2024.

In 2024, North America held the largest share of the global CRO services market, driven by the presence of well-established pharmaceutical and biotechnology industries, which drive significant demand for outsourced research and development services. Additionally, a vast network of clinical sites, hospitals, and specialized facilities, providing an ideal infrastructure for conducting large-scale clinical trials, is present in the region. Additionally, the rapid adoption of digital health solutions and decentralized trial models in the US, a significant contributor to the substantial share of the region, is further boosting CRO demand, as sponsors seek innovative ways to improve patient recruitment and retention.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply-side- 70% and Demand-side 30%
• By Designation: Managers – 45%, CXOs & Directors – 30%, and Executives – 25%
• By Region: North America – 40%, Europe -25%, Asia Pacific -25%, Latin America -5%, and the Middle East & Africa- 5%

List of Companies Profiled in the Report:

• IQVIA Inc. (US)
• ICON plc (Ireland)
• Thermo Fisher Scientific Inc. (US)
• Laboratory Corporation of America Holdings (LabCorp) (US)
• Fortrea, Inc. (US)
• Syneos Health (US)
• WuXi AppTec (China)
• Charles River Laboratories (US)
• Parexel International Corporation (US)
• Pharmaron (China)
• Medpace (US)
• SGS SA (Switzerland), Frontage Labs (US)
• Eurofins Scientific (Luxembourg)
• BioAgile (India)
• Firma Clinical Research (US)
• Acculab Life Sciences (US)
• Novotech (Australia)
• KCR S.A. (US)
• Linical (Japan)
• Advanced Clinical (US)
• Allucent (US)
• Clinical Trial Service (Netherlands)
• Guires Inc. (Pepgra Healthcare Pvt. Ltd.) (UK)
• Worldwide Clinical Trials (US)
• CTI Clinical Trial And Consulting (US)

Research Coverage

This research report categorizes the CRO services market by service type (clinical research services, early phase development services, laboratory services, consulting services, and data management services), modality (small molecules, biologics, biosimilars, medical devices), end user (pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes), and regional scope (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa). The report covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRO services market. A thorough analysis of the key industry players has provided insights into their business overview, services, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, partnerships, and acquisitions are the recent developments associated with the CRO services market.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall CRO services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (Increasing focus on decentralized trials, rising complexity and volume of trials, service flexibility offered by CROs), opportunities (regulatory focus on patient pool diversity), and challenges (challenges of patient retention and cybersecurity/intellectual property concerns) influencing the growth of the market.
• Service Development/Innovation: Detailed insights on newly launched services of the CRO services market
• Market Development: Comprehensive information about lucrative markets – the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the CRO services market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of key players, including IQVIA Inc. (US), ICON Plc (Ireland), Medpace (US), Laboratory Corporation of America Holdings (LabCorp) (US), Thermo Fisher Scientific Inc. (US), and Fortrea, Inc. (US). A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, service launches, acquisitions, partnerships, agreements, collaborations, expansions, other recent developments, investment and funding activities, brand/service comparative analysis, and vendor valuation and financial metrics of the CRO services market.

Table of Contents

1               INTRODUCTION              53

1.1           STUDY OBJECTIVES       53

1.2           MARKET DEFINITION   53

1.3           STUDY SCOPE   53

1.3.1        MARKET SEGMENTATION AND REGIONAL SCOPE                 54

1.3.2        INCLUSIONS AND EXCLUSIONS 55

1.3.3        YEARS CONSIDERED      56

1.4           CURRENCY CONSIDERED            56

1.5           STAKEHOLDERS               56

1.6           SUMMARY OF CHANGES               57

2               RESEARCH METHODOLOGY       59

2.1           RESEARCH APPROACH  59

2.1.1        SECONDARY DATA          60

2.1.1.1    Key sources of secondary data            60

2.1.1.2    Key objectives of secondary research                 60

2.1.2        PRIMARY DATA 61

2.1.2.1    Breakdown of primaries      61

2.1.2.2    Key objectives of primary research    62

2.2           MARKET ESTIMATION METHODOLOGY               62

2.2.1        COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)       63

2.2.2        MNM REPOSITORY ANALYSIS AND PRIMARY RESEARCH                 64

2.2.3        DEMAND AND SUPPLY-SIDE ANALYSIS 66

2.2.4        SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)       67

2.3           GROWTH RATE PROJECTIONS  68

2.4           DATA TRIANGULATION                71

2.5           RESEARCH ASSUMPTIONS           72

2.6           RESEARCH LIMITATIONS             73

2.7           RISK ANALYSIS  73

3               EXECUTIVE SUMMARY  74

3.1           KEY INSIGHTS AND MARKET HIGHLIGHTS          74

3.2           STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN CRO SERVICES MARKET          78

3.3           DISRUPTIVE TRENDS SHAPING CRO SERVICES MARKET                 79

3.4           HIGH GROWTH SEGMENTS AND EMERGING FRONTIERS         80

4               PREMIUM INSIGHTS       81

4.1           GLOBAL CRO SERVICES MARKET SNAPSHOT      81

4.2           NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY AND COUNTRY, 2024               82

4.3           CRO SERVICES MARKET, BY TYPE, 2024  83

4.4           CRO SERVICES MARKET, BY END USER, 2024        83

4.5           CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              84

4.6           UNMET NEEDS AND WHITE SPACES       84

4.7           STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES                 85

4.8           EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFT                 86

4.9           INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES              86

4.10         SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES       87

5               MARKET OVERVIEW       88

5.1           INTRODUCTION              88

5.2           MARKET DYNAMICS       88

5.2.1        DRIVERS               89

5.2.1.1    Rising clinical trial volume and escalating protocol complexity                 89

5.2.1.2    Growing focus on decentralized/patient-centric trials   90

5.2.1.3    Increasing preference for service flexibility      90

5.2.1.4    Technological integration   91

5.2.1.5    Growing R&D budgets and expanding late-stage pipelines                 92

5.2.2        OPPORTUNITIES              93

5.2.2.1    Shift toward regulatory compliance   93

5.2.2.2    Growing adoption of risk-based monitoring    93

5.2.2.3    Favorable reimbursement scenario    94

5.2.3        CHALLENGES    94

5.2.3.1    Patient retention  94

5.2.3.2    Cybersecurity and intellectual property challenges         95

6               INDUSTRY TRENDS         96

6.1           MARKET TRENDS             96

6.1.1        HEALTH ECONOMICS & OUTCOMES RESEARCH AND REAL-WORLD EVIDENCE             96

6.1.2        IN-SILICO TRIALS             96

6.1.3        SPECIALIZED ANALYTICS FOR EMERGING MODALITIES                 97

6.2           TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS            97

6.3           PRICING ANALYSIS          98

6.3.1        INDICATIVE PRICING ANALYSIS, BY SERVICE TYPE                 98

6.3.2        INDICATIVE PRICING ANALYSIS, BY PHASE          99

6.3.3        INDICATIVE PRICING ANALYSIS, BY REGION      99

6.4           VALUE CHAIN ANALYSIS               100

6.5           ECOSYSTEM ANALYSIS  102

6.6           INVESTMENT/FUNDING ACTIVITY          104

6.7           TECHNOLOGY ANALYSIS             105

6.7.1        KEY TECHNOLOGIES     105

6.7.1.1    Clinical trial management system      105

6.7.1.2    Randomization and trial supply management  105

6.7.1.3    Electronic Data Capture (EDC) system           106

6.7.2        COMPLEMENTARY TECHNOLOGIES       106

6.7.2.1    Model-informed drug development  106

6.7.2.2    Data management and informatics technologies             107

6.7.3        ADJACENT TECHNOLOGIES       107

6.7.3.1    Clinical trial simulation tools              107

6.8           KEY CONFERENCES AND EVENTS             108

6.9           REGULATORY LANDSCAPE         109

6.9.1        REGULATORY FRAMEWORK       109

6.9.1.1    North America      109

6.9.1.2    Europe   110

6.9.1.3    Asia Pacific            111

6.9.1.4    Rest of the World 112

6.9.2        REGULATORY ANALYSIS               113

6.9.3        REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             113

6.9.4        REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES      115

6.10         PORTER’S FIVE FORCES ANALYSIS           118

6.10.1      BARGAINING POWER OF SUPPLIERS       120

6.10.2      BARGAINING POWER OF BUYERS             120

6.10.3      THREAT OF NEW ENTRANTS      120

6.10.4      THREAT OF SUBSTITUTES          120

6.10.5      INTENSITY OF COMPETITIVE RIVALRY 121

6.11         KEY STAKEHOLDERS AND BUYING CRITERIA     121

6.11.1      KEY STAKEHOLDERS IN BUYING PROCESS           121

6.11.2      BUYING CRITERIA           122

6.12         CUSTOMER LANDSCAPE               124

6.12.1      BUDGET ALLOCATION TREND 124

6.12.2      ADOPTION BARRIER AND INTERNAL FRICTION                 124

6.13         IMPACT OF AI/GEN AI ON CRO SERVICES MARKET                 125

6.13.1      INTRODUCTION              125

6.13.2      MARKET POTENTIAL ACROSS DRUG DEVELOPMENT STAGES                 125

6.13.3      AI USE CASES     126

6.13.4      KEY COMPANIES IMPLEMENTING AI      127

6.13.5      FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM       127

6.14         IMPACT OF 2025 TRUMP TARIFF ON CRO SERVICES MARKET               127

6.14.1      INTRODUCTION              127

6.14.2      KEY TARIFF RATES          128

6.14.3      PRICE IMPACT ANALYSIS             128

6.14.4      IMPACT ON COUNTRY/REGION                128

6.14.4.1  North America (US)            128

6.14.4.2  Europe   129

6.14.4.3  Asia Pacific            129

6.14.5      IMPACT ON END-USE INDUSTRIES          130

6.14.5.1  Pharmaceutical & biotech companies                130

6.14.5.2  Medical device companies  130

6.14.5.3  Academic institutes              130

7               CRO SERVICES MARKET, BY TYPE             131

7.1           INTRODUCTION              132

7.2           CLINICAL RESEARCH SERVICES 132

7.2.1        PHASE III             138

7.2.1.1    Large-scale testing ability to assess efficacy and safety of drugs to aid growth              138

7.2.2        PHASE II               142

7.2.2.1    Growing number of pipeline products in Phase II studies to drive market    142

7.2.3        PHASE I                 145

7.2.3.1    Robust pipeline of pharmaceutical and biopharmaceutical products to support growth 145

7.2.4        PHASE IV              149

7.2.4.1    Stringent global regulations for drug safety monitoring to spur growth    149

7.3           EARLY PHASE DEVELOPMENT SERVICES              152

7.3.1        CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES             156

7.3.1.1    Growing need to meet regulatory norms for drugs to fuel market                 156

7.3.2        PRECLINICAL SERVICES                159

7.3.2.1    Pharmacokinetics/Pharmacodynamics             163

7.3.2.1.1 Rise in outsourcing services by pharmaceutical and biopharmaceutical companies to promote growth           163

7.3.2.2    Toxicology testing                 166

7.3.2.2.1 Need to prevent late-stage failures to contribute to growth                 166

7.3.2.3    Other preclinical services    170

7.3.3        DISCOVERY STUDIES     173

7.3.3.1    Increasing reliance on CRO services for target identification and validation to expedite growth              173

7.4           LABORATORY SERVICES               176

7.4.1        ANALYTICAL TESTING  180

7.4.1.1    Physical characterization     184

7.4.1.1.1 Ability to minimize product failure in late-phase development to favor growth          184

7.4.1.2    Raw material testing             187

7.4.1.2.1 Need to maintain quality of finished product to facilitate growth                 187

7.4.1.3    Batch-release testing            191

7.4.1.3.1 Need to maintain batch-to-batch consistency of pharmaceutical dosage forms to advance growth        191

7.4.1.4    Stability testing     194

7.4.1.4.1 Ability to establish drug compatibility and formulation development to aid growth 194

7.4.1.5    Other analytical testing services        198

7.4.2        BIOANALYTICAL TESTING          201

7.4.2.1    Increasing outsourcing of R&D activities to accelerate growth                 201

7.5           CONSULTING SERVICES                204

7.5.1        GROWING ADOPTION OF CONSULTING SERVICES FOR

FASTER REGULATORY APPROVALS TO BOOST MARKET                 204

7.6           DATA MANAGEMENT SERVICES                209

7.6.1        NEED TO TRACK PROGRESS OF EARLY DRUG DEVELOPMENT TO AUGMENT GROWTH             209

8               CRO SERVICES MARKET, BY THERAPEUTIC AREA                 213

8.1           INTRODUCTION              214

8.2           ONCOLOGY        215

8.2.1        BREAST CANCER              220

8.2.1.1    Increasing cases and high spending on treating breast cancer to support growth      220

8.2.2        LUNG CANCER  223

8.2.2.1    Increasing focus on developing drugs against lung cancer to foster growth    223

8.2.3        COLORECTAL CANCER 227

8.2.3.1    Increasing drug discovery and development efforts against colorectal cancer to aid growth           227

8.2.4        PROSTATE CANCER        230

8.2.4.1    Growing clinical pipeline to propel market      230

8.2.5        OTHER CANCERS             234

8.3           INFECTIOUS DISEASES 237

8.3.1        INCREASING INCIDENCE OF CHRONIC INFECTIONS TO SUPPORT GROWTH        237

8.4           CARDIOVASCULAR SYSTEM DISORDERS               241

8.4.1        HIGH MORTALITY RATES DUE TO CARDIOVASCULAR DISEASES TO FUEL MARKET       241

8.5           NEUROLOGY     245

8.5.1        GROWING INVESTMENTS IN NEUROLOGICAL DISORDER RESEARCH TO DRIVE MARKET            245

8.6           VACCINES           249

8.6.1        INCREASING FOCUS ON VACCINE DEVELOPMENT TO SPUR GROWTH 249

8.7           METABOLIC DISORDERS/ENDOCRINOLOGY      252

8.7.1        INCREASING GLOBAL DIABETES AND OBESITY POPULATION TO PROMOTE GROWTH 252

8.8           IMMUNOLOGICAL DISORDERS 256

8.8.1        GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET               256

8.9           PSYCHIATRY      259

8.9.1        RISING CASES OF PSYCHIATRIC DISORDERS AND DEPRESSION TO SUSTAIN GROWTH       259

8.10         RESPIRATORY DISORDERS          263

8.10.1      RISING INCIDENCE OF CHRONIC RESPIRATORY DISEASE TO FOSTER GROWTH  263

8.11         DERMATOLOGY               266

8.11.1      GROWING FOCUS ON DRUG DEVELOPMENT AGAINST VARIOUS SKIN CONDITIONS TO DRIVE MARKET               266

8.12         OPHTHALMOLOGY         270

8.12.1      GROWTH IN OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT MARKET          270

8.13         GASTROINTESTINAL DISEASES 273

8.13.1      RAPID LIFESTYLE AND DIETARY CHANGES TO AMPLIFY GROWTH             273

8.14         GENITOURINARY & WOMEN’S HEALTH 276

8.14.1      RISING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS AND TREATMENT TO BOLSTER GROWTH            276

8.15         HEMATOLOGY 279

8.15.1      INCREASING DRUG APPROVALS FOR DRUGS AGAINST NON-MALIGNANT HEMATOLOGICAL CONDITIONS TO SUPPORT GROWTH        279

8.16         OTHER THERAPEUTIC AREAS    283

9               CRO SERVICES MARKET, BY MODALITY 287

9.1           INTRODUCTION              288

9.2           SMALL MOLECULES       288

9.2.1        ONGOING SURGE IN PHARMACEUTICAL R&D INVESTMENTS TO SUPPORT GROWTH 288

9.3           BIOLOGICS         292

9.3.1        MONOCLONAL ANTIBODY         295

9.3.1.1    Surging demand for targeted therapies across oncology, autoimmune disorders, and infectious diseases to drive market   295

9.3.2        CELL & GENE THERAPY 299

9.3.2.1    Robust drug pipeline and R&D initiatives to drive market                 299

9.3.3        OTHER BIOLOGICS         302

9.4           MEDICAL DEVICES          305

9.4.1        RAPID INNOVATIONS IN DIAGNOSTICS, IMPLANTABLE, AND DIGITAL HEALTH TECHNOLOGIES TO FOSTER GROWTH                 305

9.5           BIOSIMILARS     309

9.5.1        MONOCLONAL ANTIBODY BIOSIMILARS              312

9.5.1.1    Rising demand for affordable therapeutic options to support growth    312

9.5.2        INSULIN               315

9.5.2.1    Increasing patent expirations to contribute to growth    315

9.5.3        COLONY STIMULATING FACTOR              318

9.5.3.1    Increasing use of colony stimulating factor during post-chemotherapy to aid growth                318

9.5.4        ERYTHROPOEITIN          321

9.5.4.1    Essential role of erythropoietin in treating anemia to stimulate growth    321

9.5.5        OTHER BIOSIMILARS     324

10            CRO SERVICES MARKET, BY END USER  328

10.1         INTRODUCTION              329

10.2         PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES       329

10.2.1      INCREASING OUTSOURCING AND PARTNERSHIPS TO ACCELERATE GROWTH 329

10.3         MEDICAL DEVICE COMPANIES 334

10.3.1      INCREASING RECOGNITION OF CRO PROVIDERS TO AUGMENT GROWTH      334

10.4         ACADEMIC INSTITUTES                338

10.4.1      CONSISTENT COLLABORATIONS BETWEEN CROS AND ACADEMIA TO INTENSIFY GROWTH       338

11            CRO SERVICES MARKET, BY REGION       342

11.1         INTRODUCTION              343

11.2         NORTH AMERICA             343

11.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 349

11.2.2      US           350

11.2.2.1  Increasing incidence of oncology indications to accelerate growth                 350

11.2.3      CANADA               356

11.2.3.1  Favorable government initiatives and high investments to support growth      356

11.3         EUROPE               361

11.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      367

11.3.2      GERMANY           368

11.3.2.1  Presence of strong pharmaceutical and biotechnology R&D infrastructure to spur growth              368

11.3.3      UK          373

11.3.3.1  Rising R&D expenditure in pharmaceutical industry to expedite growth    373

11.3.4      FRANCE                378

11.3.4.1  Increasing technological advancements and faster drug discovery and development initiatives to aid growth        378

11.3.5      ITALY    383

11.3.5.1  Short timeline for drug approvals to encourage growth 383

11.3.6      SPAIN    388

11.3.6.1  Growing investment in pharmaceutical industry to boost market                 388

11.3.7      REST OF EUROPE             393

11.4         ASIA PACIFIC     399

11.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 406

11.4.2      CHINA  407

11.4.2.1  Continued efforts on improving level of drug safety and supply to spur growth            407

11.4.3      INDIA    413

11.4.3.1  Large pool of patients and presence of highly skilled medical professionals to augment growth       413

11.4.4      JAPAN   418

11.4.4.1  Growing drug development activity to propel market    418

11.4.5      AUSTRALIA         423

11.4.5.1  Growing focus on funding opportunities to boost market                 423

11.4.6      SOUTH KOREA  428

11.4.6.1  Emerging clinical research hub to sustain growth           428

11.4.7      REST OF ASIA PACIFIC   433

11.5         LATIN AMERICA                439

11.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 444

11.5.2      BRAZIL 445

11.5.2.1  Growing focus on enhancing pharmaceutical research and production to fuel market   445

11.5.3      MEXICO                450

11.5.3.1  Increasing investments in pharma R&D to promote growth                 450

11.5.4      REST OF LATIN AMERICA             455

11.6         MIDDLE EAST   461

11.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST                 466

11.6.2      GCC COUNTRIES              467

11.6.2.1  Kingdom of Saudi Arabia (KSA)        473

11.6.2.1.1                Expanding clinical trials ecosystem to contribute to growth    473

11.6.2.2  United Arab Emirates (UAE)             478

11.6.2.2.1                Growing clinical trials activity to drive market                 478

11.6.2.2.2                Rest of GCC Countries        483

11.6.2.3  Rest of Middle East              489

11.7         AFRICA 494

11.7.1      BOOMING PHARMACEUTICAL INDUSTRY TO FACILITATE GROWTH   494

11.7.2      MACROECONOMIC OUTLOOK FOR AFRICA        499

12            COMPETITIVE LANDSCAPE         501

12.1         INTRODUCTION              501

12.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            501

12.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN

CRO SERVICES MARKET                502

12.3         REVENUE ANALYSIS, 2020–2024  503

12.4         MARKET SHARE ANALYSIS, 2024                 504

12.5         COMPANY VALUATION AND FINANCIAL METRICS                 507

12.6         BRAND/SERVICE COMPARISON 508

12.7         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 509

12.7.1      STARS   509

12.7.2      EMERGING LEADERS     509

12.7.3      PERVASIVE PLAYERS      509

12.7.4      PARTICIPANTS 509

12.7.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         511

12.7.5.1  Company footprint               511

12.7.5.2  Region footprint   512

12.7.5.3  Type footprint       513

12.8         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        514

12.8.1      PROGRESSIVE COMPANIES         514

12.8.2      RESPONSIVE COMPANIES            514

12.8.3      DYNAMIC COMPANIES  514

12.8.4      STARTING BLOCKS         514

12.8.5      COMPETITIVE BENCHMARKING               516

12.8.5.1  Detailed list of key startups/SMEs    516

12.8.5.2  Competitive benchmarking of key startups/SMEs          517

12.9         COMPETITIVE SCENARIO             518

12.9.1      SERVICE/SOLUTION LAUNCHES AND APPROVALS                 518

12.9.2      DEALS  519

12.9.3      EXPANSIONS     520

13            COMPANY PROFILES      521

13.1         KEY PLAYERS     521

13.1.1      IQVIA INC.           521

13.1.1.1  Business overview 521

13.1.1.2  Services/Solutions offered  522

13.1.1.3  Recent developments           524

13.1.1.3.1                Service/Solution launches and approvals          524

13.1.1.3.2                Deals      525

13.1.1.3.3                Other developments             527

13.1.1.4  MnM view              528

13.1.1.4.1                Key strengths        528

13.1.1.4.2                Strategic choices   528

13.1.1.4.3                Weaknesses and competitive threats 528

13.1.2      ICON PLC             529

13.1.2.1  Business overview 529

13.1.2.2  Services/Solutions offered  530

13.1.2.3  Recent developments           532

13.1.2.3.1                Service/Solution launches and approvals          532

13.1.2.3.2                Deals      532

13.1.2.3.3                Expansions             533

13.1.2.4  MnM view              533

13.1.2.4.1                Key strengths        533

13.1.2.4.2                Strategic choices   534

13.1.2.4.3                Weaknesses and competitive threats 534

13.1.3      THERMO FISHER SCIENTIFIC INC.            535

13.1.3.1  Business overview 535

13.1.3.2  Services/Solutions offered  536

13.1.3.3  Recent developments           539

13.1.3.3.1                Service/Solution launches and approvals          539

13.1.3.3.2                Deals      540

13.1.3.3.3                Expansions             541

13.1.3.4  MnM view              542

13.1.3.4.1                Key strengths        542

13.1.3.4.2                Strategic choices   542

13.1.3.4.3                Weaknesses and competitive threats 542

13.1.4      LABCORP             543

13.1.4.1  Business overview 543

13.1.4.2  Services/Solutions offered  544

13.1.4.3  Recent developments           545

13.1.4.3.1                Service/Solution launches and approvals          545

13.1.4.3.2                Deals      546

13.1.4.3.3                Expansions             547

13.1.4.3.4                Other developments             548

13.1.4.4  MnM view              548

13.1.4.4.1                Key strengths        548

13.1.4.4.2                Strategic choices   548

13.1.4.4.3                Weaknesses and competitive threats 548

13.1.5      FORTREA, INC.  549

13.1.5.1  Company overview                549

13.1.5.2  Services/Solutions offered  550

13.1.5.3  Recent developments           553

13.1.5.3.1                Service/Solution launches and approvals          553

13.1.5.3.2                Deals      554

13.1.5.3.3                Expansions             554

13.1.5.3.4                Other developments             555

13.1.5.4  MnM view              555

13.1.5.4.1                Key strengths        555

13.1.5.4.2                Strategic choices   555

13.1.5.4.3                Weaknesses and competitive threats 555

13.1.6      SYNEOS HEALTH              556

13.1.6.1  Business overview 556

13.1.6.2  Services/Solutions offered  556

13.1.6.3  Recent developments           558

13.1.6.3.1                Service/Solution launches and approvals          558

13.1.6.3.2                Deals      558

13.1.7      WUXI APPTEC   561

13.1.7.1  Business overview 561

13.1.7.2  Services/Solutions offered  562

13.1.7.3  Recent developments           564

13.1.7.3.1                Service/Solution launches and approvals          564

13.1.7.3.2                Deals      565

13.1.7.3.3                Expansions             565

13.1.8      CHARLES RIVER LABORATORIES               566

13.1.8.1  Business overview 566

13.1.8.2  Services/Solutions offered  567

13.1.8.3  Recent developments           568

13.1.8.3.1                Deals      568

13.1.8.3.2                Expansions             571

13.1.9      PAREXEL INTERNATIONAL CORPORATION         572

13.1.9.1  Business overview 572

13.1.9.2  Services/Solutions offered  573

13.1.9.3  Recent developments           574

13.1.9.3.1                Service/Solution launches and approvals          574

13.1.9.3.2                Deals      575

13.1.9.3.3                Expansions             576

13.1.10   PHARMARON     577

13.1.10.1                 Business overview 577

13.1.10.2                 Services/Solutions offered  579

13.1.11   MEDPACE            580

13.1.11.1                 Business overview 580

13.1.11.2                 Services/Solutions offered  581

13.1.12   SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA 583

13.1.12.1                 Business overview 583

13.1.12.2                 Services/Solutions offered  584

13.1.12.3                 Recent developments           586

13.1.12.3.1             Deals      586

13.1.13   FRONTAGE LABS              587

13.1.13.1                 Business overview 587

13.1.13.2                 Services/Solutions offered  588

13.1.13.3                 Recent developments           590

13.1.13.3.1             Deals      590

13.1.13.3.2             Expansions             591

13.1.13.3.3             Other developments             592

13.1.14   EUROFINS SCIENTIFIC  593

13.1.14.1                 Business overview 593

13.1.14.2                 Services/Solutions offered  594

13.1.14.3                 Recent developments           596

13.1.14.3.1             Deals      596

13.1.15   TIGERMED          597

13.1.15.1                 Business overview 597

13.1.15.2                 Services/Solutions offered  598

13.1.15.3                 Recent developments           600

13.1.15.3.1             Service/Solution launches and approvals          600

13.1.15.3.2             Deals      601

13.1.16   PSI          602

13.1.16.1                 Business overview 602

13.1.16.2                 Services/Solutions offered  602

13.1.16.3                 Recent developments           603

13.1.16.3.1             Service/Solution launches and approvals          603

13.1.16.3.2             Deals      603

13.1.16.3.3             Expansions             604

13.1.17   BIOAGILE THERAPEUTICS PRIVATE LIMITED    605

13.1.17.1                 Business overview 605

13.1.17.2                 Services/Solutions offered  605

13.1.18   FIRMA CLINICAL RESEARCH       607

13.1.18.1                 Business overview 607

13.1.18.2                 Services/Solutions offered  607

13.1.19   ACCULAB LIFE SCIENCES             608

13.1.19.1                 Business overview 608

13.1.19.2                 Services/Solutions offered  608

13.1.20   NOVOTECH        609

13.1.20.1                 Business overview 609

13.1.20.2                 Services/Solutions offered  609

13.1.20.3                 Recent developments           612

13.1.20.3.1             Deals      612

13.1.21   LINICAL                613

13.1.21.1                 Business overview 613

13.1.21.2                 Services/Solutions offered  613

13.1.21.3                 Recent developments           614

13.1.21.3.1             Deals      614

13.1.21.3.2             Expansions             614

13.1.22   ADVANCED CLINICAL   615

13.1.22.1                 Business overview 615

13.1.22.2                 Services/Solutions offered  615

13.1.22.3                 Recent developments           616

13.1.22.3.1             Deals      616

13.1.22.3.2             Expansions             617

13.2         OTHER PLAYERS              618

13.2.1      ALLUCENT          618

13.2.2      EMVENIO            619

13.2.3      GUIRES INC.       620

13.2.4      WORLDWIDE CLINICAL TRIALS 621

13.2.5      CTI CLINICAL TRIAL & CONSULTING     623

14            APPENDIX           624

14.1         DISCUSSION GUIDE        624

14.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                629

14.3         CUSTOMIZATION OPTIONS        631

14.4         RELATED REPORTS         632

14.5         AUTHOR DETAILS           633

LIST OF TABLES

TABLE 1                CRO SERVICES MARKET: INCLUSIONS AND EXCLUSIONS      55

TABLE 2                IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS  69

TABLE 3                CRO SERVICES MARKET: RISK ANALYSIS                 73

TABLE 4                CRO SERVICES MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES  85

TABLE 5                CRO SERVICES MARKET: EMERGING BUSINESS MODELS AND TARGET SEGMENTS          86

TABLE 6                CRO SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS       89

TABLE 7                INDICATIVE PRICING ANALYSIS, BY SERVICE TYPE, 2024 (USD)              98

TABLE 8                INDICATIVE PRICING ANALYSIS, BY PHASE, 2024 (USD MILLION) 99

TABLE 9                INDICATIVE PRICING ANALYSIS, BY REGION, 2024 (USD MILLION)       99

TABLE 10              CRO SERVICES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 103

TABLE 11              CRO SERVICES MARKET: KEY CONFERENCES AND EVENTS, 2025–2026                 108

TABLE 12              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  113

TABLE 13              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  114

TABLE 14              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  114

TABLE 15              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 115

TABLE 16              CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS           119

TABLE 17              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY MODALITY              122

TABLE 18              KEY BUYING CRITERIA, BY END USER    122

TABLE 19              CRO SERVICES MARKET: ADOPTION BARRIER AND INTERNAL FRICTION           124

TABLE 20              CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 132

TABLE 21              NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF AUGUST 2024, BY LOCATION 133

TABLE 22              CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS           134

TABLE 23              CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,

2023–2030 (USD MILLION)            135

TABLE 24              CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY REGION,

2023–2030 (USD MILLION)            135

TABLE 25              NORTH AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               135

TABLE 26              EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               136

TABLE 27              ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)             136

TABLE 28              LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               137

TABLE 29              MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY REGION, 2023–2030 (USD MILLION)   137

TABLE 30              GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               137

TABLE 31              CRO SERVICES MARKET FOR PHASE III, BY REGION, 2023–2030 (USD MILLION)          139

TABLE 32              NORTH AMERICA: CRO SERVICES MARKET FOR PHASE III, BY COUNTRY,

2023–2030 (USD MILLION)            139

TABLE 33              EUROPE: CRO SERVICES MARKET FOR PHASE III, BY COUNTRY,

2023–2030 (USD MILLION)            140

TABLE 34              ASIA PACIFIC: CRO SERVICES MARKET FOR PHASE III, BY COUNTRY,

2023–2030 (USD MILLION)            140

TABLE 35              LATIN AMERICA: CRO SERVICES MARKET FOR PHASE III, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 36              MIDDLE EAST: CRO SERVICES MARKET FOR PHASE III, BY REGION,

2023–2030 (USD MILLION)            141

TABLE 37              GCC COUNTRIES: CRO SERVICES MARKET FOR PHASE III, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 38              CRO SERVICES MARKET FOR PHASE II, BY REGION, 2023–2030 (USD MILLION)          142

TABLE 39              NORTH AMERICA: CRO SERVICES MARKET FOR PHASE II, BY COUNTRY,

2023–2030 (USD MILLION)            143

TABLE 40              EUROPE: CRO SERVICES MARKET FOR PHASE II, BY COUNTRY,

2023–2030 (USD MILLION)            143

TABLE 41              ASIA PACIFIC: CRO SERVICES MARKET FOR PHASE II, BY COUNTRY,

2023–2030 (USD MILLION)            144

TABLE 42              LATIN AMERICA: CRO SERVICES MARKET FOR PHASE II, BY COUNTRY,

2023–2030 (USD MILLION)            144

TABLE 43              MIDDLE EAST: CRO SERVICES MARKET FOR PHASE II, BY REGION,

2023–2030 (USD MILLION)            144

TABLE 44              GCC COUNTRIES: CRO SERVICES MARKET FOR PHASE II, BY COUNTRY,

2023–2030 (USD MILLION)            145

TABLE 45              CRO SERVICES MARKET FOR PHASE I, BY REGION, 2023–2030 (USD MILLION)          146

TABLE 46              NORTH AMERICA: CRO SERVICES MARKET FOR PHASE I, BY COUNTRY,

2023–2030 (USD MILLION)            146

TABLE 47              EUROPE: CRO SERVICES MARKET FOR PHASE I, BY COUNTRY,

2023–2030 (USD MILLION)            147

TABLE 48              ASIA PACIFIC: CRO SERVICES MARKET FOR PHASE I, BY COUNTRY,

2023–2030 (USD MILLION)            147

TABLE 49              LATIN AMERICA: CRO SERVICES MARKET FOR PHASE I, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 50              MIDDLE EAST: CRO SERVICES MARKET FOR PHASE I, BY REGION,

2023–2030 (USD MILLION)            148

TABLE 51              GCC COUNTRIES: CRO SERVICES MARKET FOR PHASE I, BY COUNTRY,

2023–2030 (USD MILLION)            148

TABLE 52              CRO SERVICES MARKET FOR PHASE IV, BY REGION, 2023–2030 (USD MILLION)          149

TABLE 53              NORTH AMERICA: CRO SERVICES MARKET FOR PHASE IV, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 54              EUROPE: CRO SERVICES MARKET FOR PHASE IV, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 55              ASIA PACIFIC: CRO SERVICES MARKET FOR PHASE IV, BY COUNTRY,

2023–2030 (USD MILLION)          151

TABLE 56              LATIN AMERICA: CRO SERVICES MARKET FOR PHASE IV, BY COUNTRY,

2023–2030 (USD MILLION)            151

TABLE 57              MIDDLE EAST: CRO SERVICES MARKET FOR PHASE IV, BY REGION,

2023–2030 (USD MILLION)            151

TABLE 58              GCC COUNTRIES: CRO SERVICES MARKET FOR PHASE IV, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 59              CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         152

TABLE 60              CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD MILLION)            153

TABLE 61              NORTH AMERICA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)       153

TABLE 62              EUROPE: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               154

TABLE 63              ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)       154

TABLE 64              LATIN AMERICA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)       155

TABLE 65              MIDDLE EAST: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY REGION, 2023–2030 (USD MILLION) 155

TABLE 66              GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)       155

TABLE 67              CRO SERVICES MARKET FOR CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES, BY REGION, 2023–2030 (USD MILLION)       156

TABLE 68              NORTH AMERICA: CRO SERVICES MARKET FOR CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)     156

TABLE 69              EUROPE: CRO SERVICES MARKET FOR CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)     157

TABLE 70              ASIA PACIFIC: CRO SERVICES MARKET FOR CHEMISTRY, MANUFACTURING,

AND CONTROL SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)            157

TABLE 71              LATIN AMERICA: CRO SERVICES MARKET FOR CHEMISTRY, MANUFACTURING,

AND CONTROL SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)            158

TABLE 72              MIDDLE EAST: CRO SERVICES MARKET FOR CHEMISTRY, MANUFACTURING,

AND CONTROL SERVICES, BY REGION, 2023–2030 (USD MILLION)            158

TABLE 73              GCC COUNTRIES: CRO SERVICES MARKET FOR CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)     158

TABLE 74              CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            159

TABLE 75              CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY REGION,

2023–2030 (USD MILLION)            160

TABLE 76              NORTH AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               160

TABLE 77              EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)            161

TABLE 78              ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               161

TABLE 79              LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               162

TABLE 80              MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY REGION, 2023–2030 (USD MILLION)                 162

TABLE 81              GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               162

TABLE 82              CRO SERVICES MARKET FOR PHARMACOKINETICS/PHARMACODYNAMICS,

BY REGION, 2023–2030 (USD MILLION)   163

TABLE 83              NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACOKINETICS/PHARMACODYNAMICS, BY COUNTRY,

2023–2030 (USD MILLION)            164

TABLE 84              EUROPE: CRO SERVICES MARKET FOR PHARMACOKINETICS/PHARMACODYNAMICS, BY COUNTRY,

2023–2030 (USD MILLION)            164

TABLE 85              ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACOKINETICS/PHARMACODYNAMICS, BY COUNTRY,

2023–2030 (USD MILLION)            165

TABLE 86              LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACOKINETICS/PHARMACODYNAMICS, BY COUNTRY,

2023–2030 (USD MILLION)            165

TABLE 87              MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACOKINETICS/PHARMACODYNAMICS, BY REGION,

2023–2030 (USD MILLION)            165

TABLE 88              GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACOKINETICS/PHARMACODYNAMICS, BY COUNTRY,

2023–2030 (USD MILLION)            166

TABLE 89              CRO SERVICES MARKET FOR TOXICOLOGY TESTING, BY REGION,

2023–2030 (USD MILLION)            167

TABLE 90              NORTH AMERICA: CRO SERVICES MARKET FOR TOXICOLOGY TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               167

TABLE 91              EUROPE: CRO SERVICES MARKET FOR TOXICOLOGY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)            168

TABLE 92              ASIA PACIFIC: CRO SERVICES MARKET FOR TOXICOLOGY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)            168

TABLE 93              LATIN AMERICA: CRO SERVICES MARKET FOR TOXICOLOGY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)            169

TABLE 94              MIDDLE EAST: CRO SERVICES MARKET FOR TOXICOLOGY TESTING, BY REGION, 2023–2030 (USD MILLION)                 169

TABLE 95              GCC COUNTRIES: CRO SERVICES MARKET FOR TOXICOLOGY TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               169

TABLE 96              CRO SERVICES MARKET FOR OTHER PRECLINICAL SERVICES, BY REGION,

2023–2030 (USD MILLION)            170

TABLE 97              NORTH AMERICA: CRO SERVICES MARKET FOR OTHER PRECLINICAL SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               170

TABLE 98              EUROPE: CRO SERVICES MARKET FOR OTHER PRECLINICAL SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               171

TABLE 99              ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER PRECLINICAL SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               171

TABLE 100            LATIN AMERICA: CRO SERVICES MARKET FOR OTHER PRECLINICAL SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               172

TABLE 101            MIDDLE EAST: CRO SERVICES MARKET FOR OTHER PRECLINICAL SERVICES,

BY REGION, 2023–2030 (USD MILLION)   172

TABLE 102            GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER PRECLINICAL SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               172

TABLE 103            CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY REGION,

2023–2030 (USD MILLION)          173

TABLE 104            NORTH AMERICA: CRO SERVICES MARKET FOR DISCOVERY STUDIES,

BY COUNTRY, 2023–2030 (USD MILLION)               173

TABLE 105            EUROPE: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY,

2023–2030 (USD MILLION)            174

TABLE 106            ASIA PACIFIC: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)                 174

TABLE 107            LATIN AMERICA: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)                 175

TABLE 108            MIDDLE EAST: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY REGION, 2023–2030 (USD MILLION)                 175

TABLE 109            GCC COUNTRIES: CRO SERVICES MARKET FOR DISCOVERY STUDIES, BY COUNTRY, 2023–2030 (USD MILLION)                 175

TABLE 110            LABORATORY SERVICES OFFERED BY KEY PLAYERS              176

TABLE 111            CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            177

TABLE 112            CRO SERVICES MARKET FOR LABORATORY SERVICES, BY REGION,

2023–2030 (USD MILLION)            177

TABLE 113            NORTH AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               177

TABLE 114            EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)            178

TABLE 115            ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)            178

TABLE 116            LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               179

TABLE 117            MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY REGION, 2023–2030 (USD MILLION)                 179

TABLE 118            GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               179

TABLE 119            CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            180

TABLE 120            CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY REGION,

2023–2030 (USD MILLION)            181

TABLE 121            NORTH AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               181

TABLE 122            EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY COUNTRY,

2023–2030 (USD MILLION)            182

TABLE 123            ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY COUNTRY, 2023–2030 (USD MILLION)                 182

TABLE 124            LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY COUNTRY, 2023–2030 (USD MILLION)                 183

TABLE 125            MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING,

BY REGION, 2023–2030 (USD MILLION)   183

TABLE 126            GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               183

TABLE 127            CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION, BY REGION,

2023–2030 (USD MILLION)          184

TABLE 128            NORTH AMERICA: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,

BY COUNTRY, 2023–2030 (USD MILLION)               185

TABLE 129            EUROPE: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,

BY COUNTRY, 2023–2030 (USD MILLION)               185

TABLE 130            ASIA PACIFIC: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,

BY COUNTRY, 2023–2030 (USD MILLION)               186

TABLE 131            LATIN AMERICA: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,

BY COUNTRY, 2023–2030 (USD MILLION)             186

TABLE 132            MIDDLE EAST: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,

BY REGION, 2023–2030 (USD MILLION)   186

TABLE 133            GCC COUNTRIES: CRO SERVICES MARKET FOR PHYSICAL CHARACTERIZATION,

BY COUNTRY, 2023–2030 (USD MILLION)               187

TABLE 134            CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY REGION,

2023–2030 (USD MILLION)            188

TABLE 135            NORTH AMERICA: CRO SERVICES MARKET FOR RAW MATERIAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               188

TABLE 136            EUROPE: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2023–2030 (USD MILLION)                 189

TABLE 137            ASIA PACIFIC: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY COUNTRY, 2023–2030 (USD MILLION)                 189

TABLE 138            LATIN AMERICA: CRO SERVICES MARKET FOR RAW MATERIAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               190

TABLE 139            MIDDLE EAST: CRO SERVICES MARKET FOR RAW MATERIAL TESTING, BY REGION, 2023–2030 (USD MILLION)            190

TABLE 140            GCC COUNTRIES: CRO SERVICES MARKET FOR RAW MATERIAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               190

TABLE 141            CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY REGION,

2023–2030 (USD MILLION)            191

TABLE 142            NORTH AMERICA: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               192

TABLE 143            EUROPE: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING, BY COUNTRY, 2023–2030 (USD MILLION)                 192

TABLE 144            ASIA PACIFIC: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               193

TABLE 145            LATIN AMERICA: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               193

TABLE 146            MIDDLE EAST: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING,

BY REGION, 2023–2030 (USD MILLION)   193

TABLE 147            GCC COUNTRIES: CRO SERVICES MARKET FOR BATCH-RELEASE TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               194

TABLE 148            CRO SERVICES MARKET FOR STABILITY TESTING, BY REGION,

2023–2030 (USD MILLION)          195

TABLE 149            NORTH AMERICA: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)                 195

TABLE 150            EUROPE: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY,

2023–2030 (USD MILLION)            196

TABLE 151            ASIA PACIFIC: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)                 196

TABLE 152            LATIN AMERICA: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)                 197

TABLE 153            MIDDLE EAST: CRO SERVICES MARKET FOR STABILITY TESTING, BY REGION, 2023–2030 (USD MILLION)                 197

TABLE 154            GCC COUNTRIES: CRO SERVICES MARKET FOR STABILITY TESTING, BY COUNTRY, 2023–2030 (USD MILLION)                 197

TABLE 155            CRO SERVICES MARKET FOR OTHER ANALYTICAL TESTING, BY REGION,

2023–2030 (USD MILLION)            198

TABLE 156            NORTH AMERICA: CRO SERVICES MARKET FOR OTHER ANALYTICAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               198

TABLE 157            EUROPE: CRO SERVICES MARKET FOR OTHER ANALYTICAL TESTING, BY COUNTRY, 2023–2030 (USD MILLION)                 199

TABLE 158            ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER ANALYTICAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               199

TABLE 159            LATIN AMERICA: CRO SERVICES MARKET FOR OTHER ANALYTICAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               200

TABLE 160            MIDDLE EAST: CRO SERVICES MARKET FOR OTHER ANALYTICAL TESTING,

BY REGION, 2023–2030 (USD MILLION)   200

TABLE 161            GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER ANALYTICAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               200

TABLE 162            CRO SERVICES MARKET FOR BIOANALYTICAL TESTING, BY REGION,

2023–2030 (USD MILLION)            201

TABLE 163            NORTH AMERICA: CRO SERVICES MARKET FOR BIOANALYTICAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               202

TABLE 164            EUROPE: CRO SERVICES MARKET FOR BIOANALYTICAL TESTING, BY COUNTRY, 2023–2030 (USD MILLION)            202

TABLE 165            ASIA PACIFIC: CRO SERVICES MARKET FOR BIOANALYTICAL TESTING, BY COUNTRY, 2023–2030 (USD MILLION)            203

TABLE 166            LATIN AMERICA: CRO SERVICES MARKET FOR BIOANALYTICAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               203

TABLE 167            MIDDLE EAST: CRO SERVICES MARKET FOR BIOANALYTICAL TESTING,

BY REGION, 2023–2030 (USD MILLION)   203

TABLE 168            GCC COUNTRIES: CRO SERVICES MARKET FOR BIOANALYTICAL TESTING,

BY COUNTRY, 2023–2030 (USD MILLION)               204

TABLE 169            CONSULTING SERVICES OFFERED BY PROMINENT PLAYERS   205

TABLE 170            CRO SERVICES MARKET FOR CONSULTING SERVICES, BY REGION,

2023–2030 (USD MILLION)            206

TABLE 171            NORTH AMERICA: CRO SERVICES MARKET FOR CONSULTING SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               206

TABLE 172            EUROPE: CRO SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)            207

TABLE 173            ASIA PACIFIC: CRO SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2023–2030 (USD MILLION)            207

TABLE 174            LATIN AMERICA: CRO SERVICES MARKET FOR CONSULTING SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               208

TABLE 175            MIDDLE EAST: CRO SERVICES MARKET FOR CONSULTING SERVICES,

BY REGION, 2023–2030 (USD MILLION)   208

TABLE 176            GCC COUNTRIES: CRO SERVICES MARKET FOR CONSULTING SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               208

TABLE 177            CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES, BY REGION,

2023–2030 (USD MILLION)            209

TABLE 178            NORTH AMERICA: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               210

TABLE 179            EUROPE: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               210

TABLE 180            ASIA PACIFIC: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               211

TABLE 181            LATIN AMERICA: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               211

TABLE 182            MIDDLE EAST: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY REGION, 2023–2030 (USD MILLION)   211

TABLE 183            GCC COUNTRIES: CRO SERVICES MARKET FOR DATA MANAGEMENT SERVICES,

BY COUNTRY, 2023–2030 (USD MILLION)               212

TABLE 184            CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)               214

TABLE 185            NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040 215

TABLE 186            CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2023–2030 (USD MILLION)                216

TABLE 187            CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)          217

TABLE 188            NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            217

TABLE 189            EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            218

TABLE 190            ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            218

TABLE 191            LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            219

TABLE 192            MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY REGION,

2023–2030 (USD MILLION)            219

TABLE 193            GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            219

TABLE 194            CRO SERVICES MARKET FOR BREAST CANCER, BY REGION,

2023–2030 (USD MILLION)            220

TABLE 195            NORTH AMERICA: CRO SERVICES MARKET FOR BREAST CANCER,

BY COUNTRY, 2023–2030 (USD MILLION)               221

TABLE 196            EUROPE: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY,

2023–2030 (USD MILLION)            221

TABLE 197            ASIA PACIFIC: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY,

2023–2030 (USD MILLION)            222

TABLE 198            LATIN AMERICA: CRO SERVICES MARKET FOR BREAST CANCER, BY COUNTRY, 2023–2030 (USD MILLION)                 222

TABLE 199            MIDDLE EAST: CRO SERVICES MARKET FOR BREAST CANCER, BY REGION,

2023–2030 (USD MILLION)            222

TABLE 200            GCC COUNTRIES: CRO SERVICES MARKET FOR BREAST CANCER,

BY COUNTRY, 2023–2030 (USD MILLION)               223

TABLE 201            CRO SERVICES MARKET FOR LUNG CANCER, BY REGION,

2023–2030 (USD MILLION)            224

TABLE 202            NORTH AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)                 224

TABLE 203            EUROPE: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY,

2023–2030 (USD MILLION)            225

TABLE 204            ASIA PACIFIC: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY,

2023–2030 (USD MILLION)            225

TABLE 205            LATIN AMERICA: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY,

2023–2030 (USD MILLION)            226

TABLE 206            MIDDLE EAST: CRO SERVICES MARKET FOR LUNG CANCER, BY REGION,

2023–2030 (USD MILLION)            226

TABLE 207            GCC COUNTRIES: CRO SERVICES MARKET FOR LUNG CANCER, BY COUNTRY, 2023–2030 (USD MILLION)                 226

TABLE 208            CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION,

2023–2030 (USD MILLION)            227

TABLE 209            NORTH AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER,

BY COUNTRY, 2023–2030 (USD MILLION)               228

TABLE 210            EUROPE: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION)            228

TABLE 211            ASIA PACIFIC: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION)            229

TABLE 212            LATIN AMERICA: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2023–2030 (USD MILLION)            229

TABLE 213            MIDDLE EAST: CRO SERVICES MARKET FOR COLORECTAL CANCER, BY REGION, 2023–2030 (USD MILLION)                 229

TABLE 214            GCC COUNTRIES: CRO SERVICES MARKET FOR COLORECTAL CANCER,

BY COUNTRY, 2023–2030 (USD MILLION)               230

TABLE 215            CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION,

2023–2030 (USD MILLION)            231

TABLE 216            NORTH AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)                 231

TABLE 217            EUROPE: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY,

2023–2030 (USD MILLION)            232

TABLE 218            ASIA PACIFIC: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)                 232

TABLE 219            LATIN AMERICA: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)                 233

TABLE 220            MIDDLE EAST: CRO SERVICES MARKET FOR PROSTATE CANCER, BY REGION, 2023–2030 (USD MILLION)                 233

TABLE 221            GCC COUNTRIES: CRO SERVICES MARKET FOR PROSTATE CANCER, BY COUNTRY, 2023–2030 (USD MILLION)                 233

TABLE 222            NUMBER OF DRUGS IN R&D PIPELINE FOR OTHER CANCERS, 2023–2024        234

TABLE 223            CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION,

2023–2030 (USD MILLION)            234

TABLE 224            NORTH AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION)                 235

TABLE 225            EUROPE: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY,

2023–2030 (USD MILLION)            235

TABLE 226            ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY,

2023–2030 (USD MILLION)            236

TABLE 227            LATIN AMERICA: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION)                 236

TABLE 228            MIDDLE EAST: CRO SERVICES MARKET FOR OTHER CANCERS, BY REGION,

2023–2030 (USD MILLION)            236

TABLE 229            GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER CANCERS, BY COUNTRY, 2023–2030 (USD MILLION)                 237

TABLE 230            CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION,

2023–2030 (USD MILLION)            238

TABLE 231            NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               238

TABLE 232            EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY INFECTIOUS DISEASES, 2023–2030 (USD MILLION)            239

TABLE 233            ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)                 239

TABLE 234            LATIN AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               240

TABLE 235            MIDDLE EAST: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)                 240

TABLE 236            GCC COUNTRIES: CRO SERVICES MARKET FOR INFECTIOUS DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               240

TABLE 237            CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION)                 242

TABLE 238            NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       242

TABLE 239            EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               243

TABLE 240            ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       243

TABLE 241            LATIN AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       244

TABLE 242            MIDDLE EAST: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2023–2030 (USD MILLION) 244

TABLE 243            GCC COUNTRIES: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)       244

TABLE 244            CRO SERVICES MARKET FOR NEUROLOGY, BY REGION,

2023–2030 (USD MILLION)            246

TABLE 245            NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            246

TABLE 246            EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            247

TABLE 247            ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            247

TABLE 248            LATIN AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            248

TABLE 249            MIDDLE EAST: CRO SERVICES MARKET FOR NEUROLOGY, BY REGION,

2023–2030 (USD MILLION)            248

TABLE 250            GCC COUNTRIES: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            248

TABLE 251            CRO SERVICES MARKET FOR VACCINES, BY REGION, 2023–2030 (USD MILLION)          249

TABLE 252            NORTH AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,

2023–2030 (USD MILLION)            249

TABLE 253            EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,

2023–2030 (USD MILLION)          250

TABLE 254            ASIA PACIFIC: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,

2023–2030 (USD MILLION)            250

TABLE 255            LATIN AMERICA: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,

2023–2030 (USD MILLION)            251

TABLE 256            MIDDLE EAST: CRO SERVICES MARKET FOR VACCINES, BY REGION,

2023–2030 (USD MILLION)            251

TABLE 257            GCC COUNTRIES: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,

2023–2030 (USD MILLION)            251

TABLE 258            CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY,

BY REGION, 2023–2030 (USD MILLION)   253

TABLE 259            NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            253

TABLE 260            EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            254

TABLE 261            ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            254

TABLE 262            LATIN AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            255

TABLE 263            MIDDLE EAST: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2023–2030 (USD MILLION)       255

TABLE 264            GCC COUNTRIES: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)            255

TABLE 265            CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION,

2023–2030 (USD MILLION)            256

TABLE 266            NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               257

TABLE 267            EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               257

TABLE 268            ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               258

TABLE 269            LATIN AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               258

TABLE 270            MIDDLE EAST: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,

BY REGION, 2023–2030 (USD MILLION)   258

TABLE 271            GCC COUNTRIES: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               259

TABLE 272            CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION,

2023–2030 (USD MILLION)            260

TABLE 273            NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,

2023–2030 (USD MILLION)            260

TABLE 274            EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,

2023–2030 (USD MILLION)            261

TABLE 275            ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,

2023–2030 (USD MILLION)            261

TABLE 276            LATIN AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,

2023–2030 (USD MILLION)            262

TABLE 277            MIDDLE EAST: CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION,

2023–2030 (USD MILLION)            262

TABLE 278            GCC COUNTRIES: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,

2023–2030 (USD MILLION)            262

TABLE 279            CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION,

2023–2030 (USD MILLION)            263

TABLE 280            NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               264

TABLE 281            EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION)            264

TABLE 282            ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               265

TABLE 283            LATIN AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)               265

TABLE 284            MIDDLE EAST: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,

BY REGION, 2023–2030 (USD MILLION)   265

TABLE 285            GCC COUNTRIES: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS,

BY COUNTRY, 2023–2030 (USD MILLION)             266

TABLE 286            CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION,

2023–2030 (USD MILLION)            267

TABLE 287            NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               267

TABLE 288            EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            268

TABLE 289            ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            268

TABLE 290            LATIN AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 269

TABLE 291            MIDDLE EAST: CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION,

2023–2030 (USD MILLION)            269

TABLE 292            GCC COUNTRIES: CRO SERVICES MARKET FOR DERMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               269

TABLE 293            CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,

2023–2030 (USD MILLION)            270

TABLE 294            NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               270

TABLE 295            EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            271

TABLE 296            ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 271

TABLE 297            LATIN AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 272

TABLE 298            MIDDLE EAST: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION,

2023–2030 (USD MILLION)            272

TABLE 299            GCC COUNTRIES: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 272

TABLE 300            CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION,

2023–2030 (USD MILLION)            273

TABLE 301            NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)             273

TABLE 302            EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               274

TABLE 303            ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               274

TABLE 304            LATIN AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               275

TABLE 305            MIDDLE EAST: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,

BY REGION, 2023–2030 (USD MILLION)   275

TABLE 306            GCC COUNTRIES: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES,

BY COUNTRY, 2023–2030 (USD MILLION)               275

TABLE 307            CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION)                 276

TABLE 308            NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 277

TABLE 309            EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,

BY COUNTRY, 2023–2030 (USD MILLION)               277

TABLE 310            ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 278

TABLE 311            LATIN AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 278

TABLE 312            MIDDLE EAST: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2023–2030 (USD MILLION) 278

TABLE 313            GCC COUNTRIES: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY COUNTRY, 2023–2030 (USD MILLION) 279

TABLE 314            CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION,

2023–2030 (USD MILLION)            280

TABLE 315            NORTH AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY,

BY COUNTRY, 2023–2030 (USD MILLION)               280

TABLE 316            EUROPE: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            281

TABLE 317            ASIA PACIFIC: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            281

TABLE 318            LATIN AMERICA: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,

2023–2030 (USD MILLION)            282

TABLE 319            MIDDLE EAST: CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION,

2023–2030 (USD MILLION)            282

TABLE 320            GCC COUNTRIES: CRO SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY, 2023–2030 (USD MILLION)                 282

TABLE 321            CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION,

2023–2030 (USD MILLION)            283

TABLE 322            NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,

BY COUNTRY, 2023–2030 (USD MILLION)               284

TABLE 323            EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION)                 284

TABLE 324            ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,

BY COUNTRY, 2023–2030 (USD MILLION)               285

TABLE 325            LATIN AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,

BY COUNTRY, 2023–2030 (USD MILLION)               285

TABLE 326            MIDDLE EAST: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,

BY REGION, 2023–2030 (USD MILLION)   285

TABLE 327            GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,

BY COUNTRY, 2023–2030 (USD MILLION)               286

TABLE 328            CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)       288

TABLE 329            CRO SERVICES MARKET FOR SMALL MOLECULES, BY REGION,

2023–2030 (USD MILLION)            289

TABLE 330            NORTH AMERICA: CRO SERVICES MARKET FOR SMALL MOLECULES,

BY COUNTRY, 2023–2030 (USD MILLION)               289

TABLE 331            EUROPE: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY,

2023–2030 (USD MILLION)          290

TABLE 332            ASIA PACIFIC: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)                 290

TABLE 333            LATIN AMERICA: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)                 291

TABLE 334            MIDDLE EAST: CRO SERVICES MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)                 291

TABLE 335            GCC COUNTRIES: CRO SERVICES MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)                 291

TABLE 336            CRO SERVICES MARKET FOR BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)          292

TABLE 337            NORTH AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY,

2023–2030 (USD MILLION)            293

TABLE 338            EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY,

2023–2030 (USD MILLION)            293

TABLE 339            ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY,

2023–2030 (USD MILLION)            294

TABLE 340            LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY,

2023–2030 (USD MILLION)            294

TABLE 341            MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY REGION,

2023–2030 (USD MILLION)            294

TABLE 342            GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY COUNTRY,

2023–2030 (USD MILLION)            295

TABLE 343            CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION)                295

TABLE 344            CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY, BY REGION,

2023–2030 (USD MILLION)            296

TABLE 345            NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY,

BY COUNTRY, 2023–2030 (USD MILLION)               296

TABLE 346            EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY, BY COUNTRY, 2023–2030 (USD MILLION)            297

TABLE 347            ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY,

BY COUNTRY, 2023–2030 (USD MILLION)               297

TABLE 348            LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY,

BY COUNTRY, 2023–2030 (USD MILLION)               298

TABLE 349            MIDDLE EAST: CRO SERVICES BIOLOGICS MARKET FOR MONOCLONAL ANTIBODY, BY REGION, 2023–2030 (USD MILLION) 298

TABLE 350            GCC COUNTRIES: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY,

BY COUNTRY, 2023–2030 (USD MILLION)               298

TABLE 351            CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION,

2023–2030 (USD MILLION)            299

TABLE 352            NORTH AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY,

BY COUNTRY, 2023–2030 (USD MILLION)               300

TABLE 353            EUROPE: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION)                 300

TABLE 354            ASIA PACIFIC: CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION)            301

TABLE 355            LATIN AMERICA: CRO SERVICES MARKET FOR CELL & GENE THERAPY,

BY COUNTRY, 2023–2030 (USD MILLION)               301

TABLE 356            MIDDLE EAST: CRO SERVICES MARKET FOR CELL & GENE THERAPY,

BY REGION, 2023–2030 (USD MILLION)   301

TABLE 357            GCC COUNTRIES: CRO SERVICES MARKET FOR CELL & GENE THERAPY,

BY COUNTRY, 2023–2030 (USD MILLION)               302

TABLE 358          CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY REGION,

2023–2030 (USD MILLION)            302

TABLE 359            NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOLOGICS,

BY COUNTRY, 2023–2030 (USD MILLION)               303

TABLE 360            EUROPE: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY,

2023–2030 (USD MILLION)            303

TABLE 361            ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)                 304

TABLE 362            LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)                 304

TABLE 363            MIDDLE EAST: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY REGION, 2023–2030 (USD MILLION)                 304

TABLE 364            GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER BIOLOGICS, BY COUNTRY, 2023–2030 (USD MILLION)                 305

TABLE 365          CRO SERVICES MARKET FOR MEDICAL DEVICES, BY REGION,

2023–2030 (USD MILLION)            306

TABLE 366            NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 306

TABLE 367            EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY,

2023–2030 (USD MILLION)            307

TABLE 368            ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 307

TABLE 369            LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 308

TABLE 370            MIDDLE EAST: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY REGION, 2023–2030 (USD MILLION)                 308

TABLE 371            GCC COUNTRIES: CRO SERVICES MARKET FOR MEDICAL DEVICES, BY COUNTRY, 2023–2030 (USD MILLION)                 308

TABLE 372            CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION,

2023–2030 (USD MILLION)            309

TABLE 373            NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,

2023–2030 (USD MILLION)            309

TABLE 374            EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,

2023–2030 (USD MILLION)            310

TABLE 375            ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,

2023–2030 (USD MILLION)          310

TABLE 376            LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,

2023–2030 (USD MILLION)            311

TABLE 377            MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY REGION,

2023–2030 (USD MILLION)            311

TABLE 378            GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,

2023–2030 (USD MILLION)            311

TABLE 379            CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2023–2030 (USD MILLION)                312

TABLE 380            CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY REGION, 2023–2030 (USD MILLION)                 312

TABLE 381            NORTH AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2023–2030 (USD MILLION)       313

TABLE 382            EUROPE: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS,

BY COUNTRY, 2023–2030 (USD MILLION)               313

TABLE 383            ASIA PACIFIC: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2023–2030 (USD MILLION)       314

TABLE 384            LATIN AMERICA: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2023–2030 (USD MILLION)       314

TABLE 385            MIDDLE EAST: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY REGION, 2023–2030 (USD MILLION) 314

TABLE 386            GCC COUNTRIES: CRO SERVICES MARKET FOR MONOCLONAL ANTIBODY BIOSIMILARS, BY COUNTRY, 2023–2030 (USD MILLION)       315

TABLE 387            CRO SERVICES MARKET FOR INSULIN, BY REGION, 2023–2030 (USD MILLION)          315

TABLE 388            NORTH AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,

2023–2030 (USD MILLION)            316

TABLE 389            EUROPE: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,

2023–2030 (USD MILLION)            316

TABLE 390            ASIA PACIFIC: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,

2023–2030 (USD MILLION)            317

TABLE 391            LATIN AMERICA: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,

2023–2030 (USD MILLION)            317

TABLE 392            MIDDLE EAST: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,

2023–2030 (USD MILLION)            317

TABLE 393            GCC COUNTRIES: CRO SERVICES MARKET FOR INSULIN, BY COUNTRY,

2023–2030 (USD MILLION)          318

TABLE 394            CRO SERVICES MARKET FOR COLONY STIMULATING FACTOR, BY REGION,

2023–2030 (USD MILLION)            318

TABLE 395            NORTH AMERICA: CRO SERVICES MARKET FOR COLONY STIMULATING FACTOR,

BY COUNTRY, 2023–2030 (USD MILLION)               319

TABLE 396            EUROPE: CRO SERVICES MARKET FOR COLONY STIMULATING FACTOR,

BY COUNTRY, 2023–2030 (USD MILLION)               319

TABLE 397            ASIA PACIFIC: CRO SERVICES MARKET FOR COLONY STIMULATING FACTOR,

BY COUNTRY, 2023–2030 (USD MILLION)               320

TABLE 398            LATIN AMERICA: CRO SERVICES MARKET FOR COLONY STIMULATING FACTOR,

BY COUNTRY, 2023–2030 (USD MILLION)               320

TABLE 399            MIDDLE EAST: CRO SERVICES MARKET FOR COLONY STIMULATING FACTOR,

BY REGION, 2023–2030 (USD MILLION)   320

TABLE 400            GCC COUNTRIES: CRO SERVICES BIOSIMILARS MARKET FOR COLONY STIMULATING FACTOR, BY COUNTRY, 2023–2030 (USD MILLION)            321

TABLE 401            CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION,

2023–2030 (USD MILLION)            321

TABLE 402            NORTH AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2023–2030 (USD MILLION)                 322

TABLE 403            EUROPE: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY,

2023–2030 (USD MILLION)            322

TABLE 404            ASIA PACIFIC: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2023–2030 (USD MILLION)                 323

TABLE 405            LATIN AMERICA: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2023–2030 (USD MILLION)                 323

TABLE 406            MIDDLE EAST: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY REGION,

2023–2030 (USD MILLION)            323

TABLE 407            GCC COUNTRIES: CRO SERVICES MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2023–2030 (USD MILLION)                 324

TABLE 408            CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION,

2023–2030 (USD MILLION)            324

TABLE 409            NORTH AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2023–2030 (USD MILLION)                 325

TABLE 410            EUROPE: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY,

2023–2030 (USD MILLION)            325

TABLE 411            ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2023–2030 (USD MILLION)                 326

TABLE 412            LATIN AMERICA: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2023–2030 (USD MILLION)                 326

TABLE 413            MIDDLE EAST: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY REGION, 2023–2030 (USD MILLION)                 326

TABLE 414            GCC COUNTRIES: CRO SERVICES MARKET FOR OTHER BIOSIMILARS, BY COUNTRY, 2023–2030 (USD MILLION)                 327

TABLE 415            CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)       329

TABLE 416            CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION)   331

TABLE 417            NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)               331

TABLE 418            EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)               332

TABLE 419            ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)               332

TABLE 420            LATIN AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)               333

TABLE 421            MIDDLE EAST: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION)   333

TABLE 422            GCC COUNTRIES: CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)               333

TABLE 423            CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION,

2023–2030 (USD MILLION)            335

TABLE 424            NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,

BY COUNTRY, 2023–2030 (USD MILLION)               335

TABLE 425            EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,

BY COUNTRY, 2023–2030 (USD MILLION)               336

TABLE 426            ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,

BY COUNTRY, 2023–2030 (USD MILLION)               336

TABLE 427            LATIN AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,

BY COUNTRY, 2023–2030 (USD MILLION)               337

TABLE 428            MIDDLE EAST: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,

BY REGION, 2023–2030 (USD MILLION)   337

TABLE 429            GCC COUNTRIES: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES,

BY COUNTRY, 2023–2030 (USD MILLION)               337

TABLE 430            CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION,

2023–2030 (USD MILLION)            338

TABLE 431            NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2023–2030 (USD MILLION)               339

TABLE 432            EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)            339

TABLE 433            ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)            340

TABLE 434            LATIN AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2023–2030 (USD MILLION)               340

TABLE 435            MIDDLE EAST: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2023–2030 (USD MILLION)                 340

TABLE 436            GCC COUNTRIES: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES,

BY COUNTRY, 2023–2030 (USD MILLION)               341

TABLE 437            CRO SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 343

TABLE 438            NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            344

TABLE 439            NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)                345

TABLE 440            NORTH AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY PHASE, 2023–2030 (USD MILLION)      345

TABLE 441            NORTH AMERICA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION) 346

TABLE 442            NORTH AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         346

TABLE 443            NORTH AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         346

TABLE 444            NORTH AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING,

BY TYPE, 2023–2030 (USD MILLION)         347

TABLE 445            NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            347

TABLE 446            NORTH AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            347

TABLE 447            NORTH AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            348

TABLE 448            NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            348

TABLE 449            NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            349

TABLE 450            NORTH AMERICA: CRO SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            349

TABLE 451            NORTH AMERICA: KEY MACROECONOMIC INDICATORS      350

TABLE 452            US: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 351

TABLE 453            US: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 352

TABLE 454            US: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         352

TABLE 455            US: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            352

TABLE 456            US: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            353

TABLE 457            US: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            353

TABLE 458            US: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)            353

TABLE 459            US: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION)                354

TABLE 460            US: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            354

TABLE 461            US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)               355

TABLE 462            US: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            355

TABLE 463            US: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)       356

TABLE 464            CANADA: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            357

TABLE 465            CANADA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)            357

TABLE 466            CANADA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         358

TABLE 467            CANADA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            358

TABLE 468            CANADA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)          358

TABLE 469            CANADA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            359

TABLE 470            CANADA: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   359

TABLE 471            CANADA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            359

TABLE 472            CANADA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)          360

TABLE 473            CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            360

TABLE 474            CANADA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            361

TABLE 475          CANADA: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            361

TABLE 476            EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            362

TABLE 477            EUROPE: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            362

TABLE 478            EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 363

TABLE 479            EUROPE: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         363

TABLE 480            EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            363

TABLE 481            EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            364

TABLE 482            EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            364

TABLE 483            EUROPE: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   364

TABLE 484            EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)          365

TABLE 485            EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            365

TABLE 486            EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            366

TABLE 487            EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            366

TABLE 488            EUROPE: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            367

TABLE 489            EUROPE: KEY MACROECONOMIC INDICATORS                 368

TABLE 490            GERMANY: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            369

TABLE 491            GERMANY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY PHASE, 2023–2030 (USD MILLION)      369

TABLE 492            GERMANY: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION)            370

TABLE 493            GERMANY: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            370

TABLE 494            GERMANY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            370

TABLE 495            GERMANY: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2023–2030 (USD MILLION)                 371

TABLE 496            GERMANY: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   371

TABLE 497            GERMANY: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            371

TABLE 498            GERMANY: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            372

TABLE 499            GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            372

TABLE 500            GERMANY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)          373

TABLE 501            GERMANY: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                373

TABLE 502            UK: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 374

TABLE 503            UK: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 374

TABLE 504            UK: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         375

TABLE 505            UK: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            375

TABLE 506            UK: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            375

TABLE 507            UK: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            376

TABLE 508            UK: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)            376

TABLE 509            UK: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION)                376

TABLE 510            UK: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            377

TABLE 511            UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)               377

TABLE 512            UK: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            378

TABLE 513            UK: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            378

TABLE 514            FRANCE: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            379

TABLE 515            FRANCE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 379

TABLE 516            FRANCE: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         380

TABLE 517            FRANCE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            380

TABLE 518            FRANCE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            380

TABLE 519            FRANCE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            381

TABLE 520            FRANCE: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   381

TABLE 521            FRANCE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            381

TABLE 522            FRANCE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            382

TABLE 523            FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            382

TABLE 524            FRANCE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            383

TABLE 525            FRANCE: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            383

TABLE 526            ITALY: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)       384

TABLE 527            ITALY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 384

TABLE 528            ITALY: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         385

TABLE 529            ITALY: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            385

TABLE 530            ITALY: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            385

TABLE 531            ITALY: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            386

TABLE 532            ITALY: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)            386

TABLE 533            ITALY: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            386

TABLE 534            ITALY: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            387

TABLE 535            ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            387

TABLE 536          ITALY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            388

TABLE 537            ITALY: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            388

TABLE 538            SPAIN: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)       389

TABLE 539            SPAIN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 389

TABLE 540            SPAIN: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         390

TABLE 541            SPAIN: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)          390

TABLE 542            SPAIN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            390

TABLE 543            SPAIN: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            391

TABLE 544            SPAIN: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)            391

TABLE 545            SPAIN: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            391

TABLE 546            SPAIN: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            392

TABLE 547            SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            392

TABLE 548          SPAIN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            393

TABLE 549            SPAIN: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            393

TABLE 550            REST OF EUROPE: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)                394

TABLE 551            REST OF EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)            395

TABLE 552            REST OF EUROPE: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION) 395

TABLE 553            REST OF EUROPE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         395

TABLE 554            REST OF EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         396

TABLE 555            REST OF EUROPE: CRO SERVICES MARKET FOR ANALYTICAL TESTING,

BY TYPE, 2023–2030 (USD MILLION)         396

TABLE 556            REST OF EUROPE: CRO SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            396

TABLE 557            REST OF EUROPE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            397

TABLE 558            REST OF EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            397

TABLE 559            REST OF EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            398

TABLE 560            REST OF EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)          398

TABLE 561            REST OF EUROPE: CRO SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            399

TABLE 562            ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     400

TABLE 563            ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            400

TABLE 564            ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY PHASE, 2023–2030 (USD MILLION)      401

TABLE 565            ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION) 401

TABLE 566            ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 401

TABLE 567            ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 402

TABLE 568            ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)          402

TABLE 569            ASIA PACIFIC: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   402

TABLE 570            ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            403

TABLE 571            ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            403

TABLE 572            ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            404

TABLE 573            ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            404

TABLE 574            ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                405

TABLE 575            ASIA PACIFIC: KEY MACROECONOMIC INDICATORS      407

TABLE 576            CHINA: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)       408

TABLE 577            CHINA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 409

TABLE 578            CHINA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         409

TABLE 579            CHINA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            409

TABLE 580            CHINA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            410

TABLE 581            CHINA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            410

TABLE 582            CHINA: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)            410

TABLE 583          CHINA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            411

TABLE 584            CHINA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            411

TABLE 585            CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            412

TABLE 586            CHINA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            412

TABLE 587            CHINA: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            413

TABLE 588            INDIA: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)       414

TABLE 589            INDIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 414

TABLE 590            INDIA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)       415

TABLE 591            INDIA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            415

TABLE 592            INDIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            415

TABLE 593            INDIA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            416

TABLE 594            INDIA: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)            416

TABLE 595            INDIA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            416

TABLE 596            INDIA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            416

TABLE 597            INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            417

TABLE 598          INDIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)          418

TABLE 599            INDIA: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            418

TABLE 600            JAPAN: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)       419

TABLE 601            JAPAN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 419

TABLE 602            JAPAN: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         420

TABLE 603            JAPAN: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            420

TABLE 604            JAPAN: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            420

TABLE 605            JAPAN: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            421

TABLE 606            JAPAN: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)            421

TABLE 607          JAPAN: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            421

TABLE 608            JAPAN: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            422

TABLE 609            JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            422

TABLE 610            JAPAN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            423

TABLE 611            JAPAN: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            423

TABLE 612            AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            424

TABLE 613            AUSTRALIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY PHASE, 2023–2030 (USD MILLION)      424

TABLE 614            AUSTRALIA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION)            425

TABLE 615            AUSTRALIA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            425

TABLE 616            AUSTRALIA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            425

TABLE 617            AUSTRALIA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            426

TABLE 618            AUSTRALIA: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   426

TABLE 619            AUSTRALIA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            426

TABLE 620            AUSTRALIA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            427

TABLE 621            AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)          427

TABLE 622            AUSTRALIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            428

TABLE 623            AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                428

TABLE 624            SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)                429

TABLE 625            SOUTH KOREA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY PHASE, 2023–2030 (USD MILLION)      429

TABLE 626            SOUTH KOREA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION) 430

TABLE 627            SOUTH KOREA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 430

TABLE 628            SOUTH KOREA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 430

TABLE 629            SOUTH KOREA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2023–2030 (USD MILLION)                 431

TABLE 630            SOUTH KOREA: CRO SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            431

TABLE 631            SOUTH KOREA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            431

TABLE 632            SOUTH KOREA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            432

TABLE 633            SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            432

TABLE 634            SOUTH KOREA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            433

TABLE 635            SOUTH KOREA: CRO SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            433

TABLE 636            REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            434

TABLE 637            REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)            434

TABLE 638            REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION)       435

TABLE 639            REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         435

TABLE 640            REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR LABORATORY SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         435

TABLE 641            REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ANALYTICAL TESTING,

BY TYPE, 2023–2030 (USD MILLION)         436

TABLE 642            REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            436

TABLE 643            REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            437

TABLE 644            REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2023–2030 (USD MILLION)  437

TABLE 645            REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            438

TABLE 646            REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            438

TABLE 647            REST OF ASIA PACIFIC: CRO SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            439

TABLE 648            LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)                440

TABLE 649            LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY PHASE, 2023–2030 (USD MILLION)      440

TABLE 650            LATIN AMERICA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION) 441

TABLE 651            LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         441

TABLE 652            LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES,

BY TYPE, 2023–2030 (USD MILLION)       441

TABLE 653            LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING,

BY TYPE, 2023–2030 (USD MILLION)         442

TABLE 654            LATIN AMERICA: CRO SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            442

TABLE 655            LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            442

TABLE 656            LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)          443

TABLE 657            LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)          443

TABLE 658            LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            444

TABLE 659            LATIN AMERICA: CRO SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            444

TABLE 660            LATIN AMERICA: KEY MACROECONOMIC INDICATORS      445

TABLE 661            BRAZIL: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)       446

TABLE 662            BRAZIL: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 446

TABLE 663            BRAZIL: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         447

TABLE 664            BRAZIL: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            447

TABLE 665            BRAZIL: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            447

TABLE 666            BRAZIL: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            448

TABLE 667            BRAZIL: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)            448

TABLE 668            BRAZIL: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            448

TABLE 669            BRAZIL: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            449

TABLE 670            BRAZIL: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            449

TABLE 671            BRAZIL: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            450

TABLE 672            BRAZIL: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            450

TABLE 673            MEXICO: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            451

TABLE 674            MEXICO: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY PHASE, 2023–2030 (USD MILLION)      451

TABLE 675            MEXICO: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         452

TABLE 676            MEXICO: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            452

TABLE 677            MEXICO: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            452

TABLE 678            MEXICO: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            453

TABLE 679            MEXICO: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   453

TABLE 680            MEXICO: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            453

TABLE 681            MEXICO: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            454

TABLE 682            MEXICO: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            454

TABLE 683            MEXICO: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            455

TABLE 684            MEXICO: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            455

TABLE 685            REST OF LATIN AMERICA: CRO SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            456

TABLE 686            REST OF LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)       456

TABLE 687            REST OF LATIN AMERICA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION)            457

TABLE 688            REST OF LATIN AMERICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         457

TABLE 689            REST OF LATIN AMERICA: CRO SERVICES MARKET FOR LABORATORY SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         457

TABLE 690            REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING,

BY TYPE, 2023–2030 (USD MILLION)         458

TABLE 691            REST OF LATIN AMERICA: CRO SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            458

TABLE 692            REST OF LATIN AMERICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE, 2023–2030 (USD MILLION)                 459

TABLE 693            REST OF LATIN AMERICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2023–2030 (USD MILLION)                 459

TABLE 694            REST OF LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            460

TABLE 695            REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2023–2030 (USD MILLION)                 460

TABLE 696            REST OF LATIN AMERICA: CRO SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            461

TABLE 697          MIDDLE EAST: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            462

TABLE 698            MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY PHASE, 2023–2030 (USD MILLION)      462

TABLE 699            MIDDLE EAST: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION) 463

TABLE 700            MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 463

TABLE 701            MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 463

TABLE 702            MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            464

TABLE 703            MIDDLE EAST: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)   464

TABLE 704            MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            464

TABLE 705            MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            465

TABLE 706            MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            465

TABLE 707            MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            466

TABLE 708            MIDDLE EAST: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                466

TABLE 709            MIDDLE EAST: KEY MACROECONOMIC INDICATORS      467

TABLE 710            GCC COUNTRIES: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)                468

TABLE 711            GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY PHASE, 2023–2030 (USD MILLION)      468

TABLE 712            GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION) 469

TABLE 713            GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 469

TABLE 714            GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2023–2030 (USD MILLION)                 469

TABLE 715            GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2023–2030 (USD MILLION)                 470

TABLE 716            GCC COUNTRIES: CRO SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            470

TABLE 717            GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            470

TABLE 718            GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            471

TABLE 719            GCC COUNTRIES: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            471

TABLE 720            GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            472

TABLE 721            GCC COUNTRIES: CRO SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            472

TABLE 722            GCC COUNTRIES: CRO SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            472

TABLE 723            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            473

TABLE 724            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)             473

TABLE 725            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION)   474

TABLE 726            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2023–2030 (USD MILLION)       474

TABLE 727            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2023–2030 (USD MILLION)       474

TABLE 728            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE, 2023–2030 (USD MILLION)       475

TABLE 729            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            475

TABLE 730            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR BIOLOGICS,

BY TYPE, 2023–2030 (USD MILLION)         476

TABLE 731            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR BIOSIMILARS,

BY TYPE, 2023–2030 (USD MILLION)         476

TABLE 732            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)            477

TABLE 733            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET FOR ONCOLOGY,

BY TYPE, 2023–2030 (USD MILLION)         477

TABLE 734            KINGDOM OF SAUDI ARABIA (KSA): CRO SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            478

TABLE 735            UAE: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)       479

TABLE 736            UAE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)                 479

TABLE 737            UAE: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         480

TABLE 738            UAE: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            480

TABLE 739            UAE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            480

TABLE 740            UAE: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            481

TABLE 741            UAE: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)            481

TABLE 742            UAE: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            481

TABLE 743            UAE: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            482

TABLE 744            UAE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)               482

TABLE 745            UAE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)          483

TABLE 746            UAE: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            483

TABLE 747            REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)          484

TABLE 748            REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)       484

TABLE 749            REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION)            485

TABLE 750            REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE, 2023–2030 (USD MILLION)            485

TABLE 751            REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE, 2023–2030 (USD MILLION)            485

TABLE 752            REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR ANALYTICAL TESTING,

BY TYPE, 2023–2030 (USD MILLION)         486

TABLE 753            REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            486

TABLE 754            REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR BIOLOGICS,

BY TYPE, 2023–2030 (USD MILLION)         487

TABLE 755            REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR BIOSIMILARS,

BY TYPE, 2023–2030 (USD MILLION)         487

TABLE 756            REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)                 488

TABLE 757            REST OF GCC COUNTRIES: CRO SERVICES MARKET FOR ONCOLOGY,

BY TYPE, 2023–2030 (USD MILLION)         488

TABLE 758            REST OF GCC COUNTRIES: CRO SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            489

TABLE 759          REST OF MIDDLE EAST: CRO SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)            489

TABLE 760            REST OF MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2023–2030 (USD MILLION)            490

TABLE 761            REST OF MIDDLE EAST: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES, BY TYPE, 2023–2030 (USD MILLION)       490

TABLE 762            REST OF MIDDLE EAST: CRO SERVICES MARKET FOR PRECLINICAL SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         490

TABLE 763            REST OF MIDDLE EAST: CRO SERVICES MARKET FOR LABORATORY SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         491

TABLE 764            REST OF MIDDLE EAST: CRO SERVICES MARKET FOR ANALYTICAL TESTING,

BY TYPE, 2023–2030 (USD MILLION)         491

TABLE 765          REST OF MIDDLE EAST: CRO SERVICES MARKET, BY MODALITY,

2023–2030 (USD MILLION)            491

TABLE 766            REST OF MIDDLE EAST: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            492

TABLE 767            REST OF MIDDLE EAST: CRO SERVICES MARKET FOR BIOSIMILARS,

BY TYPE, 2023–2030 (USD MILLION)       492

TABLE 768          REST OF MIDDLE EAST: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            493

TABLE 769            REST OF MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,

2023–2030 (USD MILLION)            493

TABLE 770          REST OF MIDDLE EAST: CRO SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            494

TABLE 771            AFRICA: CRO SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)       495

TABLE 772            AFRICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,

BY PHASE, 2023–2030 (USD MILLION)      495

TABLE 773            AFRICA: CRO SERVICES MARKET FOR EARLY PHASE DEVELOPMENT SERVICES,

BY TYPE, 2023–2030 (USD MILLION)         496

TABLE 774            AFRICA: CRO SERVICES MARKET FOR PRECLINICAL SERVICES, BY TYPE,

2023–2030 (USD MILLION)            496

TABLE 775            AFRICA: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,

2023–2030 (USD MILLION)            496

TABLE 776            AFRICA: CRO SERVICES MARKET FOR ANALYTICAL TESTING, BY TYPE,

2023–2030 (USD MILLION)            497

TABLE 777            AFRICA: CRO SERVICES MARKET, BY MODALITY, 2023–2030 (USD MILLION)            497

TABLE 778            AFRICA: CRO SERVICES MARKET FOR BIOLOGICS, BY TYPE,

2023–2030 (USD MILLION)            497

TABLE 779            AFRICA: CRO SERVICES MARKET FOR BIOSIMILARS, BY TYPE,

2023–2030 (USD MILLION)            498

TABLE 780            AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA,

2023–2030 (USD MILLION)            498

TABLE 781            AFRICA: CRO SERVICES MARKET FOR ONCOLOGY MARKET, BY TYPE,

2023–2030 (USD MILLION)            499

TABLE 782            AFRICA: CRO SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)            499

TABLE 783            AFRICA: KEY MACROECONOMIC INDICATORS                 500

TABLE 784            OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN CRO SERVICES MARKET, JANUARY 2021–AUGUST 2025        502

TABLE 785            CRO SERVICES MARKET: DEGREE OF COMPETITION 505

TABLE 786            CRO SERVICES MARKET: REGION FOOTPRINT                 512

TABLE 787            CRO SERVICES MARKET: TYPE FOOTPRINT                 513

TABLE 788            CRO SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES              516

TABLE 789            CRO SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES          517

TABLE 790            CRO SERVICES MARKET: SERVICE/SOLUTION LAUNCHES AND APPROVALS, JANUARY 2021–AUGUST 2025                 518

TABLE 791            CRO SERVICES MARKET: DEALS, JANUARY 2021–AUGUST 2025     519

TABLE 792            CRO SERVICES MARKET: EXPANSIONS, JANUARY 2021–AUGUST 2025           520

TABLE 793            IQVIA INC.: COMPANY OVERVIEW            521

TABLE 794            IQVIA INC.: SERVICES/SOLUTIONS OFFERED                 522

TABLE 795            IQVIA INC.: SERVICE/SOLUTION LAUNCHES AND APPROVALS,

JANUARY 2021–AUGUST 2025       524

TABLE 796            IQVIA INC.: DEALS, JANUARY 2021–AUGUST 2025                 525

TABLE 797            IQVIA INC.: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2025           527

TABLE 798            ICON PLC: COMPANY OVERVIEW             529

TABLE 799            ICON PLC: SERVICES/SOLUTIONS OFFERED                 530

TABLE 800            ICON PLC: SERVICE/SOLUTION LAUNCHES AND APPROVALS,

JANUARY 2021–AUGUST 2025       532

TABLE 801            ICON PLC: DEALS, JANUARY 2021–AUGUST 2025                 532

TABLE 802            ICON PLC: EXPANSIONS, JANUARY 2021–AUGUST 2025     533

TABLE 803            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          535

TABLE 804            THERMO FISHER SCIENTIFIC INC.: SERVICES/SOLUTIONS OFFERED              536

TABLE 805            THERMO FISHER SCIENTIFIC, INC.: SERVICE/SOLUTION LAUNCHES AND APPROVALS, JANUARY 2021–AUGUST 2025           539

TABLE 806            THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–AUGUST 2025       540

TABLE 807          THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2021–AUGUST 2025       541

TABLE 808            LABCORP: COMPANY OVERVIEW             543

TABLE 809            LABCORP: SERVICES/SOLUTIONS OFFERED                 544

TABLE 810            LABCORP: SERVICE/SOLUTION LAUNCHES AND APPROVALS,

JANUARY 2021–AUGUST 2025       545

TABLE 811            LABCORP: DEALS, JANUARY 2021–AUGUST 2025                 546

TABLE 812            LABCORP: EXPANSIONS, JANUARY 2021–AUGUST 2025     547

TABLE 813            LABCORP: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2025           548

TABLE 814            FORTREA, INC.: COMPANY OVERVIEW  549

TABLE 815            FORTREA, INC.: SERVICES/SOLUTIONS OFFERED             550

TABLE 816            FORTREA, INC.: SERVICE/SOLUTION LAUNCHES AND APPROVALS,

JANUARY 2021–AUGUST 2025       553

TABLE 817            FORTREA, INC.: DEALS, JANUARY 2021–AUGUST 2025        554

TABLE 818            FORTREA, INC.: EXPANSIONS, JANUARY 2021–AUGUST 2025     554

TABLE 819            FORTREA, INC.: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2025       555

TABLE 820            SYNEOS HEALTH: COMPANY OVERVIEW                 556

TABLE 821            SYNEOS HEALTH: SERVICES/SOLUTIONS OFFERED             556

TABLE 822            SYNEOS HEALTH: SERVICE/SOLUTION LAUNCHES AND APPROVALS,

JANUARY 2021–AUGUST 2025       558

TABLE 823            SYNEOS HEALTH: DEALS, JANUARY 2021–AUGUST 2025     558

TABLE 824            WUXI APPTEC: COMPANY OVERVIEW    561

TABLE 825            WUXI APPTEC: SERVICES/SOLUTIONS OFFERED                 562

TABLE 826            WUXI APPTEC: SERVICE/SOLUTION LAUNCHES AND APPROVALS,

JANUARY 2021–AUGUST 2025       564

TABLE 827            WUXI APPTEC: DEALS, JANUARY 2021–AUGUST 2025        565

TABLE 828            WUXI APPTEC: EXPANSIONS, JANUARY 2021–AUGUST 2025     565

TABLE 829            CHARLES RIVER LABORATORIES: COMPANY OVERVIEW          566

TABLE 830            CHARLES RIVER LABORATORIES: SERVICES/SOLUTIONS OFFERED              567

TABLE 831            CHARLES RIVER LABORATORIES: DEALS, JANUARY 2021–AUGUST 2025       568

TABLE 832            CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2021–AUGUST 2025       571

TABLE 833            PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW   572

TABLE 834            PAREXEL INTERNATIONAL CORPORATION: SERVICES/SOLUTIONS OFFERED              573

TABLE 835            PAREXEL INTERNATIONAL CORPORATION: SERVICE/SOLUTION LAUNCHES AND APPROVALS, JANUARY 2021–AUGUST 2025           574

TABLE 836            PAREXEL INTERNATIONAL CORPORATION: DEALS, JANUARY 2021–AUGUST 2025       575

TABLE 837            PAREXEL INTERNATIONAL CORPORATION: EXPANSIONS,

JANUARY 2021–AUGUST 2025       576

TABLE 838            PHARMARON: COMPANY OVERVIEW     577

TABLE 839            PHARMARON: SERVICES/SOLUTIONS OFFERED                 579

TABLE 840            MEDPACE: COMPANY OVERVIEW             580

TABLE 841            MEDPACE: SERVICES/SOLUTIONS OFFERED                 581

TABLE 842            SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY OVERVIEW   583

TABLE 843            SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: SERVICES/SOLUTIONS OFFERED              584

TABLE 844            SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: DEALS,

JANUARY 2021–AUGUST 2025       586

TABLE 845            FRONTAGE LABS: COMPANY OVERVIEW                 587

TABLE 846            FRONTAGE LABS: SERVICES/SOLUTIONS OFFERED             588

TABLE 847            FRONTAGE LABS: DEALS, JANUARY 2021–AUGUST 2025     590

TABLE 848            FRONTAGE LABS: EXPANSIONS, JANUARY 2021–AUGUST 2025     591

TABLE 849            FRONTAGE LABS: OTHER DEVELOPMENTS, JANUARY 2021–AUGUST 2025       592

TABLE 850            EUROFINS SCIENTIFIC: COMPANY OVERVIEW                 593

TABLE 851            EUROFINS SCIENTIFIC: SERVICES/SOLUTIONS OFFERED             594

TABLE 852            EUROFINS SCIENTIFIC: DEALS, JANUARY 2021–AUGUST 2025     596

TABLE 853            TIGERMED: COMPANY OVERVIEW          597

TABLE 854            TIGERMED: SERVICES/SOLUTIONS OFFERED                 598

TABLE 855            TIGERMED: SERVICE/SOLUTION LAUNCHES AND APPROVALS,

JANUARY 2021–AUGUST 2025       600

TABLE 856            TIGERMED: DEALS, JANUARY 2021–AUGUST 2025        601

TABLE 857            PSI: COMPANY OVERVIEW           602

TABLE 858            PSI: SERVICES/SOLUTIONS OFFERED     602

TABLE 859            PSI: SERVICE/SOLUTION LAUNCHES AND APPROVALS,

JANUARY 2021–AUGUST 2025       603

TABLE 860            PSI: DEALS, JANUARY 2021–AUGUST 2025                 603

TABLE 861            PSI: EXPANSIONS, JANUARY 2021–AUGUST 2025                 604

TABLE 862            BIOAGILE: COMPANY OVERVIEW             605

TABLE 863            BIOAGILE: SERVICES/SOLUTIONS OFFERED                 605

TABLE 864            FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW          607

TABLE 865            FIRMA CLINICAL RESEARCH: SERVICES/SOLUTIONS OFFERED              607

TABLE 866            ACCULAB LIFE SCIENCES: COMPANY OVERVIEW          608

TABLE 867            ACCULAB LIFE SCIENCES: SERVICES/SOLUTIONS OFFERED              608

TABLE 868            NOVOTECH: COMPANY OVERVIEW        609

TABLE 869            NOVOTECH: SERVICES/SOLUTIONS OFFERED                 609

TABLE 870            NOVOTECH: DEALS, JANUARY 2021–JULY 2025                 612

TABLE 871            LINICAL: COMPANY OVERVIEW                613

TABLE 872            LINICAL: SERVICES/SOLUTIONS OFFERED                 613

TABLE 873            LINICAL: DEALS, JANUARY 2021–AUGUST 2025                 614

TABLE 874            LINICAL: EXPANSIONS, JANUARY 2021–AUGUST 2025        614

TABLE 875            ADVANCED CLINICAL: COMPANY OVERVIEW                 615

TABLE 876            ADVANCED CLINICAL: SERVICES/SOLUTIONS OFFERED             615

TABLE 877            ADVANCED CLINICAL: DEALS, JANUARY 2021–AUGUST 2025     616

TABLE 878            ADVANCED CLINICAL: EXPANSIONS, JANUARY 2021–AUGUST 2025           617

TABLE 879            ALLUCENT: COMPANY OVERVIEW          618

TABLE 880            EMVENIO: COMPANY OVERVIEW             619

TABLE 881            GUIRES INC.: COMPANY OVERVIEW        620

TABLE 882            WORLDWIDE CLINICAL TRIALS: COMPANY OVERVIEW          621

TABLE 883            CTI CLINICAL TRIAL & CONSULTING: COMPANY OVERVIEW   623

LIST OF FIGURES

FIGURE 1              CRO SERVICES MARKET SEGMENTATION AND REGIONAL SCOPE            54

FIGURE 2              CRO SERVICES MARKET: RESEARCH DESIGN                 59

FIGURE 3              CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES (DEMAND- AND SUPPLY-SIDE PARTICIPANTS)                 61

FIGURE 4              GLOBAL CRO SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024      62

FIGURE 5              GLOBAL CRO SERVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH), 2024             63

FIGURE 6              ILLUSTRATIVE EXAMPLE OF IQVIA INC.: REVENUE SHARE ANALYSIS, 2024               64

FIGURE 7              CRO SERVICES MARKET SIZE VALIDATION FROM PRIMARY SOURCES            65

FIGURE 8              CRO SERVICES MARKET: SUPPLY-SIDE AND DEMAND-SIDE

ANALYSIS AND TRIANGULATION             66

FIGURE 9              CRO SERVICES MARKET: DEMAND-SIDE ANALYSIS, 2024  66

FIGURE 10            TOP-DOWN APPROACH                67

FIGURE 11            GLOBAL CRO SERVICES MARKET: CAGR PROJECTIONS, 2025–2030               69

FIGURE 12            CRO SERVICES MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS       70

FIGURE 13            CRO SERVICES MARKET: DATA TRIANGULATION METHODOLOGY         71

FIGURE 14            CRO SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION) 74

FIGURE 15            CRO SERVICES MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION)       75

FIGURE 16            CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION)         76

FIGURE 17            CRO SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)       77

FIGURE 18            REGIONAL SNAPSHOT OF CRO SERVICES MARKET               78

FIGURE 19            INCREASING CLINICAL PIPELINE AND RISING TRIAL VOLUME TO DRIVE MARKET        81

FIGURE 20            US AND SMALL MOLECULES SEGMENT LED NORTH AMERICAN MARKET IN 2024       82

FIGURE 21            CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR

LARGEST SHARE IN 2024                83

FIGURE 22            PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES

SEGMENT DOMINATED MARKET IN 2024              83

FIGURE 23            CHINA TO REGISTER HIGHER CAGR DURING FORECAST PERIOD         84

FIGURE 24            CRO SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES     88

FIGURE 25            ACTIVE PHARMACEUTICAL PIPELINE, 2013–2024                 92

FIGURE 26            REVENUE SHIFT AND NEW REVENUE POCKETS FOR CRO SERVICES MARKET      97

FIGURE 27            INDICATIVE PRICING ANALYSIS, BY REGION, 2024 (USD MILLION)       100

FIGURE 28            CRO SERVICES MARKET: VALUE CHAIN ANALYSIS            101

FIGURE 29            CRO SERVICES MARKET: ECOSYSTEM ANALYSIS                 103

FIGURE 30            CRO SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS           119

FIGURE 31            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY MODALITY              121

FIGURE 32            KEY BUYING CRITERIA, BY END USER    122

FIGURE 33            DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2023 VS. 2024       133

FIGURE 34            PROPORTION OF PIPELINE IN DEVELOPMENT FOR CANCER, 2013–2024                 216

FIGURE 35            ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000–2045 (MILLION)                252

FIGURE 36            ANNUAL DRUG APPROVALS BY CENTER FOR DRUG EVALUATION AND

RESEARCH (FDA), 2012–2024        330

FIGURE 37            R&D SPENDING OF PHRMA MEMBER COMPANIES, 2012–2023  330

FIGURE 38            US FDA DE NOVO MEDICAL DEVICE APPROVALS, 2012–2024  334

FIGURE 39            NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT          344

FIGURE 40            GLOBAL DISTRIBUTION OF R&D COMPANIES, JANUARY 2024 VS. JANUARY 2025               351

FIGURE 41            ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT          405

FIGURE 42            CRO SERVICES MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024                504

FIGURE 43            MARKET SHARE ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET, 2024     505

FIGURE 44            EV/EBITDA OF KEY VENDORS   507

FIGURE 45            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS                507

FIGURE 46            CRO SERVICES MARKET: BRAND/SERVICE COMPARISON   508

FIGURE 47            CRO SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024         510

FIGURE 48            CRO SERVICES MARKET: COMPANY FOOTPRINT       511

FIGURE 49            CRO SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 515

FIGURE 50            IQVIA INC.: COMPANY SNAPSHOT (2024)                 522

FIGURE 51            ICON PLC: COMPANY SNAPSHOT (2024)                 530

FIGURE 52            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)             536

FIGURE 53            LABCORP: COMPANY SNAPSHOT (2024)                 544

FIGURE 54            FORTREA, INC.: COMPANY SNAPSHOT (2024)                 549

FIGURE 55            WUXI APPTEC: COMPANY SNAPSHOT (2024)                 562

FIGURE 56            CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2024)             567

FIGURE 57            PHARMARON: COMPANY SNAPSHOT (2024)                 578

FIGURE 58            MEDPACE: COMPANY SNAPSHOT (2024)                 581

FIGURE 59            SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA: COMPANY SNAPSHOT (2024)      584

FIGURE 60            FRONTAGE LABS: COMPANY SNAPSHOT (2024)                 588

FIGURE 61            EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2024)    594

FIGURE 62            TIGERMED: COMPANY SNAPSHOT (2024)                 598

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧